JP2007015963A - Patch - Google Patents
Patch Download PDFInfo
- Publication number
- JP2007015963A JP2007015963A JP2005197986A JP2005197986A JP2007015963A JP 2007015963 A JP2007015963 A JP 2007015963A JP 2005197986 A JP2005197986 A JP 2005197986A JP 2005197986 A JP2005197986 A JP 2005197986A JP 2007015963 A JP2007015963 A JP 2007015963A
- Authority
- JP
- Japan
- Prior art keywords
- support
- patch
- adhesive
- adhesive layer
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000853 adhesive Substances 0.000 claims abstract description 51
- 230000001070 adhesive effect Effects 0.000 claims abstract description 51
- 239000012790 adhesive layer Substances 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 239000000178 monomer Substances 0.000 claims abstract description 37
- 239000002759 woven fabric Substances 0.000 claims abstract description 34
- 239000002998 adhesive polymer Substances 0.000 claims abstract description 28
- 239000002216 antistatic agent Substances 0.000 claims abstract description 21
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 20
- 229920001971 elastomer Polymers 0.000 claims abstract description 16
- 239000000806 elastomer Substances 0.000 claims abstract description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- -1 polyethylene Polymers 0.000 claims description 66
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 39
- 239000010410 layer Substances 0.000 claims description 32
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 18
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 229920006132 styrene block copolymer Polymers 0.000 claims description 12
- 239000003945 anionic surfactant Substances 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 239000002280 amphoteric surfactant Substances 0.000 claims description 8
- 239000002736 nonionic surfactant Substances 0.000 claims description 7
- 229920000728 polyester Polymers 0.000 claims description 7
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003093 cationic surfactant Substances 0.000 claims description 5
- 229940057995 liquid paraffin Drugs 0.000 claims description 5
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 102000011782 Keratins Human genes 0.000 abstract description 7
- 108010076876 Keratins Proteins 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 description 27
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 238000004873 anchoring Methods 0.000 description 17
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 238000004299 exfoliation Methods 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 230000003068 static effect Effects 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 230000005611 electricity Effects 0.000 description 11
- 239000011505 plaster Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 229920000139 polyethylene terephthalate Polymers 0.000 description 10
- 239000005020 polyethylene terephthalate Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 229960003237 betaine Drugs 0.000 description 7
- 239000012943 hotmelt Substances 0.000 description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 229920001400 block copolymer Polymers 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000005037 alkyl phenyl group Chemical group 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 229920001195 polyisoprene Polymers 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229940022663 acetate Drugs 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229920003051 synthetic elastomer Polymers 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- 235000007586 terpenes Nutrition 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- PVVATGNFHKTPTA-UHFFFAOYSA-N 1-methylsulfinyloctane Chemical compound CCCCCCCCS(C)=O PVVATGNFHKTPTA-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000009940 knitting Methods 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
- 229960003329 sulfinpyrazone Drugs 0.000 description 2
- 239000005061 synthetic rubber Substances 0.000 description 2
- 229940104261 taurate Drugs 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 description 1
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- SQUNAWUMZGQQJD-UHFFFAOYSA-N 1-(4-ethylphenyl)-2-methyl-3-(piperidin-1-yl)propan-1-one Chemical compound C1=CC(CC)=CC=C1C(=O)C(C)CN1CCCCC1 SQUNAWUMZGQQJD-UHFFFAOYSA-N 0.000 description 1
- FLNXBVJLPJNOSI-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 FLNXBVJLPJNOSI-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- NJPQAIBZIHNJDO-UHFFFAOYSA-N 1-dodecylpyrrolidin-2-one Chemical compound CCCCCCCCCCCCN1CCCC1=O NJPQAIBZIHNJDO-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- WJDJWDHXZBNQNE-UHFFFAOYSA-M 1-octadecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 WJDJWDHXZBNQNE-UHFFFAOYSA-M 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- YFVBASFBIJFBAI-UHFFFAOYSA-M 1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=CC=C1 YFVBASFBIJFBAI-UHFFFAOYSA-M 0.000 description 1
- GLXBPZNFNSLJBS-UHFFFAOYSA-N 11-methyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCC(C)C GLXBPZNFNSLJBS-UHFFFAOYSA-N 0.000 description 1
- VFFDVELHRCMPLY-UHFFFAOYSA-N 12-methyltridecan-1-amine Chemical compound CC(C)CCCCCCCCCCCN VFFDVELHRCMPLY-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- HBKBEZURJSNABK-MWJPAGEPSA-N 2,3-dihydroxypropyl (1r,4ar,4br,10ar)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylate Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(=O)OCC(O)CO HBKBEZURJSNABK-MWJPAGEPSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- BKUWWVKLLKXDJK-UHFFFAOYSA-N 2-(dimethylamino)icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(N(C)C)C(O)=O BKUWWVKLLKXDJK-UHFFFAOYSA-N 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- KKXGXWCLPVABEP-UHFFFAOYSA-N 2-(tetradecylamino)acetic acid Chemical compound CCCCCCCCCCCCCCNCC(O)=O KKXGXWCLPVABEP-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-HOSYLAQJSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NC[13C](O)=O VRPJIFMKZZEXLR-HOSYLAQJSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- VNUREHWOFQRPGE-UHFFFAOYSA-N 2-[2-dodecyl-1-(2-hydroxyethyl)-4,5-dihydroimidazol-1-ium-1-yl]acetate Chemical compound CCCCCCCCCCCCC1=NCC[N+]1(CCO)CC([O-])=O VNUREHWOFQRPGE-UHFFFAOYSA-N 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- FRPAVHFNOFSNDR-UHFFFAOYSA-N 3-(2,4-dioxo-1,3-thiazolidin-3-yl)propanoic acid Chemical compound OC(=O)CCN1C(=O)CSC1=O FRPAVHFNOFSNDR-UHFFFAOYSA-N 0.000 description 1
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- IZSHZLKNFQAAKX-UHFFFAOYSA-N 5-cyclopenta-2,4-dien-1-ylcyclopenta-1,3-diene Chemical group C1=CC=CC1C1C=CC=C1 IZSHZLKNFQAAKX-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- AOMZHDJXSYHPKS-DROYEMJCSA-L Amido Black 10B Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC2=CC(S([O-])(=O)=O)=C(\N=N\C=3C=CC=CC=3)C(O)=C2C(N)=C1\N=N\C1=CC=C(N(=O)=O)C=C1 AOMZHDJXSYHPKS-DROYEMJCSA-L 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- RJPWESHPIMRNNM-UHFFFAOYSA-N Bunitrolol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)COC1=CC=CC=C1C#N RJPWESHPIMRNNM-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- XYGSFNHCFFAJPO-UHFFFAOYSA-N Chlophedianol hydrochloride Chemical compound Cl.C=1C=CC=C(Cl)C=1C(O)(CCN(C)C)C1=CC=CC=C1 XYGSFNHCFFAJPO-UHFFFAOYSA-N 0.000 description 1
- RZXLPPRPEOUENN-UHFFFAOYSA-N Chlorfenson Chemical compound C1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=C(Cl)C=C1 RZXLPPRPEOUENN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 229920002633 Kraton (polymer) Polymers 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- WQVZLXWQESQGIF-UHFFFAOYSA-N Labetalol hydrochloride Chemical compound Cl.C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 WQVZLXWQESQGIF-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- LEROTMJVBFSIMP-UHFFFAOYSA-N Mebutamate Chemical compound NC(=O)OCC(C)(C(C)CC)COC(N)=O LEROTMJVBFSIMP-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- LGCMKPRGGJRYGM-UHFFFAOYSA-N Osalmid Chemical compound C1=CC(O)=CC=C1NC(=O)C1=CC=CC=C1O LGCMKPRGGJRYGM-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920013623 Solprene Polymers 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- RSLNRVYIRDVHLY-UHFFFAOYSA-N Tulobuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC=CC=C1Cl RSLNRVYIRDVHLY-UHFFFAOYSA-N 0.000 description 1
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229960000852 alprenolol hydrochloride Drugs 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 229960001280 amantadine hydrochloride Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 229960001931 ampicillin sodium Drugs 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 229960001510 betahistine mesylate Drugs 0.000 description 1
- YTIJUXVIZLYQTB-UHFFFAOYSA-N bethanidine sulfate Chemical compound [O-]S([O-])(=O)=O.CN\C(=[NH+]/C)NCC1=CC=CC=C1.CN\C(=[NH+]/C)NCC1=CC=CC=C1 YTIJUXVIZLYQTB-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229950008581 bunitrolol Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- RTYJTGSCYUUYAL-YCAHSCEMSA-L carbenicillin disodium Chemical compound [Na+].[Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C([O-])=O)C1=CC=CC=C1 RTYJTGSCYUUYAL-YCAHSCEMSA-L 0.000 description 1
- 229940098391 carbetapentane citrate Drugs 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- 229960003016 cefoxitin sodium Drugs 0.000 description 1
- FHRSHSOEWXUORL-HDJSIYSDSA-N cetraxate Chemical compound C1C[C@@H](C[NH3+])CC[C@@H]1C(=O)OC1=CC=C(CCC([O-])=O)C=C1 FHRSHSOEWXUORL-HDJSIYSDSA-N 0.000 description 1
- 229950009533 cetraxate Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960004375 ciclopirox olamine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960002925 clonidine hydrochloride Drugs 0.000 description 1
- 229960002544 cloperastine Drugs 0.000 description 1
- 229960003026 cloxacillin sodium Drugs 0.000 description 1
- SCLZRKVZRBKZCR-SLINCCQESA-M cloxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl SCLZRKVZRBKZCR-SLINCCQESA-M 0.000 description 1
- PIQVDUKEQYOJNR-VZXSFKIWSA-N cocaine hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@H]2CC[C@@H]([NH+]2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 PIQVDUKEQYOJNR-VZXSFKIWSA-N 0.000 description 1
- 229960003771 cocaine hydrochloride Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- HZTMGWSBSDLALI-UHFFFAOYSA-N dimorpholamine Chemical compound C1COCCN1C(=O)N(CCCC)CCN(CCCC)C(=O)N1CCOCC1 HZTMGWSBSDLALI-UHFFFAOYSA-N 0.000 description 1
- 229950003539 dimorpholamine Drugs 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Natural products C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- OWQUZNMMYNAXSL-UHFFFAOYSA-N diphenylpyraline Chemical compound C1CN(C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OWQUZNMMYNAXSL-UHFFFAOYSA-N 0.000 description 1
- 229960000879 diphenylpyraline Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229960002565 eperisone Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BXOUVIIITJXIKB-UHFFFAOYSA-N ethene;styrene Chemical group C=C.C=CC1=CC=CC=C1 BXOUVIIITJXIKB-UHFFFAOYSA-N 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- NUQDEHHKOXSIEA-UHFFFAOYSA-N glymidine sodium Chemical compound [Na+].N1=CC(OCCOC)=CN=C1[N-]S(=O)(=O)C1=CC=CC=C1 NUQDEHHKOXSIEA-UHFFFAOYSA-N 0.000 description 1
- 229950011212 glymidine sodium Drugs 0.000 description 1
- 229960003050 guanabenz acetate Drugs 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 229960002102 imipramine hydrochloride Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940018448 isoproterenol hydrochloride Drugs 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- 229960003091 labetalol hydrochloride Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960002339 lobeline Drugs 0.000 description 1
- 229930013610 lobeline Natural products 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960004119 mebutamate Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960002532 methamphetamine hydrochloride Drugs 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- FGSJNNQVSUVTPW-UHFFFAOYSA-N methoxyphenamine hydrochloride Chemical compound Cl.CNC(C)CC1=CC=CC=C1OC FGSJNNQVSUVTPW-UHFFFAOYSA-N 0.000 description 1
- 229960000659 methoxyphenamine hydrochloride Drugs 0.000 description 1
- CMUHZRATLMUDJI-UHFFFAOYSA-N methyl 2h-pyridine-1-carboxylate Chemical compound COC(=O)N1CC=CC=C1 CMUHZRATLMUDJI-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LZULAZTXJLWELL-UHFFFAOYSA-N methyl hex-5-ynoate Chemical compound COC(=O)CCCC#C LZULAZTXJLWELL-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960001300 metoprolol tartrate Drugs 0.000 description 1
- VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 description 1
- 229960001070 mexiletine hydrochloride Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 229960001499 neostigmine bromide Drugs 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical class CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229950011258 osalmid Drugs 0.000 description 1
- PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000022196 parasitic skin disease Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002742 polystyrene-block-poly(ethylene/propylene) -block-polystyrene Polymers 0.000 description 1
- 229920005996 polystyrene-poly(ethylene-butylene)-polystyrene Polymers 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229940094472 prenylamine lactate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- BJPJNTKRKALCPP-UHFFFAOYSA-N prilocaine hydrochloride Chemical compound [Cl-].CCC[NH2+]C(C)C(=O)NC1=CC=CC=C1C BJPJNTKRKALCPP-UHFFFAOYSA-N 0.000 description 1
- 229960003253 procainamide hydrochloride Drugs 0.000 description 1
- ABTXGJFUQRCPNH-UHFFFAOYSA-N procainamide hydrochloride Chemical compound [H+].[Cl-].CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 ABTXGJFUQRCPNH-UHFFFAOYSA-N 0.000 description 1
- 229960001586 procarbazine hydrochloride Drugs 0.000 description 1
- 229960002789 procaterol hydrochloride Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- MLGWTHRHHANFCC-UHFFFAOYSA-N prop-2-en-1-amine;hydrochloride Chemical compound Cl.NCC=C MLGWTHRHHANFCC-UHFFFAOYSA-N 0.000 description 1
- 229960005482 propicillin potassium Drugs 0.000 description 1
- ULBKMFLWMIGVOJ-CFXUUZMDSA-M propicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(CC)OC1=CC=CC=C1 ULBKMFLWMIGVOJ-CFXUUZMDSA-M 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 229940066293 respiratory stimulants Drugs 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960002961 ticlopidine hydrochloride Drugs 0.000 description 1
- MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 description 1
- 229960004402 tiopronin Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- CEYYIKYYFSTQRU-UHFFFAOYSA-M trimethyl(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)C CEYYIKYYFSTQRU-UHFFFAOYSA-M 0.000 description 1
- 229960004846 tulobuterol hydrochloride Drugs 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229920006305 unsaturated polyester Polymers 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229960000883 warfarin potassium Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
本発明は貼付剤に関し、より詳しくは、粘着剤層と帯電防止剤を含有する支持体とを少なくとも備える貼付剤に関する。 The present invention relates to a patch, and more particularly to a patch comprising at least an adhesive layer and a support containing an antistatic agent.
通常、貼付剤は、不織布又は織布からなる支持体に粘着性を有する膏体を直接塗布、あるいは一旦剥離フィルムに該膏体を塗布し支持体に転写することにより展膏するという製造工程を経て製造される。 Usually, the patch has a manufacturing process in which an adhesive paste is directly applied to a support made of a nonwoven fabric or a woven fabric, or the paste is spread by applying the paste to a release film and transferring it to the support. It is manufactured after.
上記のような工程を有する貼付剤の製造方法においては、通常の不織布又は織布からなる支持体を用いると製造中に静電気が支持体に蓄積し、該支持体に皺やよれが発生する原因となっていた。これを回避しながら製造するために製造効率が極めて低くなるという問題があった。無論、製造工程中に静電気を放電する装置を設置し、静電気を除去することも考えられるが、設備投資に費用がかかり、また完全に静電気を除去できないという問題があった。 In the method for producing a patch having the steps as described above, if a support made of a normal nonwoven fabric or woven fabric is used, static electricity accumulates on the support during production, and the cause of wrinkling and twisting on the support is caused. It was. In order to manufacture while avoiding this, there is a problem that the manufacturing efficiency becomes extremely low. Of course, it is conceivable to install a device that discharges static electricity during the manufacturing process and remove the static electricity, but there is a problem that the capital investment is expensive and the static electricity cannot be completely removed.
一方、製造された貼付剤は、製品として市場に出回り、患者の患部に貼付されて適用される。このように用いられる貼付剤の特性としては、粘着剤層から支持体が剥離しないこと、すなわち支持体と粘着剤層の高い投錨性が要求される。粘着剤層から支持体が剥離すると、粘着剤層が皮膚に後残りするという不都合を生じるためである。 On the other hand, the manufactured patch is put on the market as a product and is applied to an affected part of a patient. As a characteristic of the patch used in this manner, the support does not peel from the pressure-sensitive adhesive layer, that is, a high anchoring property between the support and the pressure-sensitive adhesive layer is required. This is because when the support is peeled from the pressure-sensitive adhesive layer, the pressure-sensitive adhesive layer is left behind on the skin.
このように、支持体と粘着剤層との間には十分な粘着力による投錨性が必要であるが、これに対し、粘着剤層と皮膚との間の粘着力が過度に強い場合には、貼付剤の適用時間終了後、貼付剤を皮膚から剥離する際に角質層まで剥離してしまい、皮膚のかぶれや皮膚刺激の原因となる場合がある。 In this way, anchorage with sufficient adhesive force is required between the support and the adhesive layer, whereas when the adhesive force between the adhesive layer and the skin is excessively strong. After the application time of the patch, the stratum corneum is peeled off when the patch is peeled from the skin, which may cause skin irritation or skin irritation.
粘着剤層と皮膚との間の粘着力をコントロールするため、例えば、特許文献1及び2には、液状ポリイソプレン及び/又はポリイソプレンを含むブロック共重合体を粘着剤層の基剤の主成分とした貼付剤が提案されている。
しかしながら、上記のような液状ポリイソプレン及び/又はポリイソプレンを含むブロック共重合体を粘着剤層の基剤の成分とした貼付剤であっても、粘着剤層と皮膚との間の粘着力、並びに、支持体と粘着剤層との間の粘着力を適切な水準にそれぞれコントロールすることが困難であった。また、特許文献1及び2に記載された貼付剤に使用している支持体では、製造中に静電気が蓄積することを防止できず、製造効率を十分に高くできず、低コスト化が困難であった。 However, even in the case of a patch comprising a liquid polyisoprene and / or a block copolymer containing polyisoprene as a base component of the adhesive layer, the adhesive force between the adhesive layer and the skin, In addition, it is difficult to control the adhesive force between the support and the adhesive layer to an appropriate level. Moreover, in the support body used for the patch described in Patent Documents 1 and 2, static electricity cannot be prevented from accumulating during production, production efficiency cannot be sufficiently increased, and cost reduction is difficult. there were.
そこで、本発明の目的は、低コスト化が容易であり、粘着剤層と支持体との間に十分な粘着力を確保しながら、皮膚から剥離する際に角質剥離を十分に防止できる貼付剤を提供することにある。 Therefore, an object of the present invention is to provide a patch that can be easily reduced in cost and can sufficiently prevent keratin exfoliation when peeling from the skin while ensuring sufficient adhesive force between the adhesive layer and the support. Is to provide.
本発明者らは、上記目的を達成すべく鋭意検討を行った結果、粘着剤層に粘着性の基剤と、該基剤と相溶性のあるオイルとを所定比で含有させ、帯電防止剤を含有する支持体に当該粘着剤層を展膏して貼付剤とすることで、上記目的を達成できることを見出し、本発明を完成させるに至った。 As a result of intensive studies to achieve the above object, the present inventors have included an adhesive base and an oil compatible with the base in a predetermined ratio in the adhesive layer, and an antistatic agent. It has been found that the above-mentioned object can be achieved by spreading the pressure-sensitive adhesive layer on a support containing bismuth to form a patch, and the present invention has been completed.
すなわち、本発明は、支持体と前記支持体上に形成された粘着剤層とを備える貼付剤において、前記粘着剤層は、粘着性を有する基剤、オイル及び薬物を含有し、前記基剤は、少なくともエラストマーと粘着付与剤からなる粘着性組成物、及び/又は、総炭素数5以上の不飽和モノマーをモノマー単位として含む粘着性高分子、から構成され、前記オイルは、前記粘着性組成物及び前記粘着性高分子と相溶性のあるオイルであり、当該オイルの含有量は、前記粘着性組成物及び前記粘着性高分子の合計100質量部に対して60〜200質量部であり、前記支持体は、帯電防止剤を含む不織布又は織布であることを特徴とする。 That is, the present invention provides a patch comprising a support and a pressure-sensitive adhesive layer formed on the support, wherein the pressure-sensitive adhesive layer contains an adhesive base, oil, and drug, and the base Is composed of at least an adhesive composition comprising an elastomer and a tackifier, and / or an adhesive polymer containing an unsaturated monomer having a total carbon number of 5 or more as a monomer unit, and the oil is the adhesive composition The oil content is 60 to 200 parts by mass with respect to a total of 100 parts by mass of the adhesive composition and the adhesive polymer. The support is a nonwoven fabric or a woven fabric containing an antistatic agent.
一般に、粘着剤層に含まれる粘着性を有する基剤はマイナスに帯電する傾向があり、織布又は不織布からなる支持体もマイナスに帯電する傾向があるため、支持体と粘着剤層との間の粘着力、即ち投錨性、が低下する傾向があるが、本発明の貼付剤によれば、支持体と粘着剤層との間の投錨性が十分に向上することが確認されている。その理由は明らかではないが、本発明の貼付剤では、粘着剤層において、粘着性組成物及び前記粘着性高分子の合計に対するオイルの質量比を一般の貼付剤より多くすることで粘着剤層中の基剤の量が相対的に低下する一方、支持体中に帯電防止剤を導入することで支持体の帯電が抑えられ、その結果、粘着剤層の帯電と支持体の帯電による投錨性低下への影響が抑えられるためではないかと考えられる。 In general, the adhesive base contained in the pressure-sensitive adhesive layer tends to be negatively charged, and the support made of woven or non-woven fabric also tends to be negatively charged. However, according to the patch of the present invention, it has been confirmed that the anchoring property between the support and the adhesive layer is sufficiently improved. The reason is not clear, but in the patch of the present invention, the pressure-sensitive adhesive layer can be obtained by increasing the mass ratio of oil to the total of the pressure-sensitive adhesive composition and the pressure-sensitive adhesive polymer in the pressure-sensitive adhesive layer. While the amount of the base in the substrate is relatively reduced, the charging of the support is suppressed by introducing an antistatic agent into the support. As a result, the anchoring property due to the charging of the adhesive layer and the charging of the support is reduced. This may be because the impact on the decline is suppressed.
また粘着剤層において、粘着性組成物及び前記粘着性高分子の合計に対するオイルの質量比が一般の貼付剤よりも大きくなっているため、粘着剤層と皮膚との間の粘着力を適度なものにすることができる。このため、本発明の貼付剤を患者に貼付した後に剥離しても、角質剥離が十分に防止され、剥離時の痛みも低減される。
さらに、粘着剤層にオイルが多く含有されることで、粘着剤層が適度に軟化し、皮膚への密着性が向上する。このため、粘着剤層に含まれる薬物の十分に高い経皮吸収性が得られる。
更にまた、本発明の貼付剤においては、支持体に帯電防止剤が含まれていることにより、支持体が帯電防止機能を有する。従って、本発明の貼付剤を製造する際、支持体を構成する織布や不織布の帯電が十分に防止され、皺やよれの発生が十分に防止されるため、製造効率が向上する。その結果、貼付剤の低コスト化が容易となる。
In the pressure-sensitive adhesive layer, the mass ratio of the oil to the total of the pressure-sensitive adhesive composition and the pressure-sensitive polymer is larger than that of a general patch, so that the pressure-sensitive adhesive force between the pressure-sensitive adhesive layer and the skin is moderate. Can be a thing. For this reason, even if it peels after sticking the patch of this invention to a patient, keratin peeling is fully prevented and the pain at the time of peeling is also reduced.
Furthermore, since the pressure-sensitive adhesive layer contains a large amount of oil, the pressure-sensitive adhesive layer is appropriately softened and the adhesion to the skin is improved. For this reason, sufficiently high transdermal absorbability of the drug contained in the pressure-sensitive adhesive layer can be obtained.
Furthermore, in the patch of the present invention, since the antistatic agent is contained in the support, the support has an antistatic function. Therefore, when producing the patch of the present invention, charging of the woven fabric or nonwoven fabric constituting the support is sufficiently prevented, and generation of wrinkles and twists is sufficiently prevented, so that production efficiency is improved. As a result, cost reduction of the patch becomes easy.
なお、本発明の貼付剤においては、粘着剤層の一部を支持体中に浸透していることが好ましい。この場合、支持体と粘着剤層との間の投錨性をより向上させることができる。 In the patch of the present invention, it is preferable that a part of the pressure-sensitive adhesive layer penetrates into the support. In this case, the anchoring property between the support and the pressure-sensitive adhesive layer can be further improved.
また、本発明の貼付剤の支持体は帯電防止剤を含んでおり、これにより製造中に静電気が蓄積することを防止でき、静電気に起因する皺やよれの発生を抑制できるため、製造効率を十分に高くできる。このため、貼付剤の低コスト化が容易となる。 In addition, the support of the patch of the present invention contains an antistatic agent, which can prevent static electricity from accumulating during production, and can suppress the generation of wrinkles and kinks caused by static electricity. Can be high enough. For this reason, cost reduction of the patch becomes easy.
粘着性組成物を構成するエラストマーとしては、スチレン系ブロックコポリマーが適しており、特に、スチレン含有量が10〜30質量%且つジブロック体含有量が40質量%以下のスチレン−イソプレン−スチレンブロックコポリマーが好ましい。 As the elastomer constituting the adhesive composition, a styrene-based block copolymer is suitable, and in particular, a styrene-isoprene-styrene block copolymer having a styrene content of 10 to 30% by mass and a diblock body content of 40% by mass or less. Is preferred.
粘着性組成物を構成するエラストマーとして、このようなスチレン系ブロックコポリマーを使用すると、皮膚への付着性、角質剥離の防止、支持体と粘着剤層の投錨性のすべてにおいて、より顕著な改善が図れるようになる。 When such a styrenic block copolymer is used as an elastomer constituting the adhesive composition, there are more remarkable improvements in all of the adhesion to the skin, prevention of exfoliation of the skin, and anchorage of the support and the adhesive layer. It will come to be able to plan.
総炭素数5以上の不飽和モノマーをモノマー単位として含む粘着性高分子としては、アルキル基の炭素数が4〜22のアルキル(メタ)アクリレートをモノマー単位として含む粘着性高分子が適している。ここで(メタ)アクリレートとは、アクリレート又はメタクリレートの意味である。 As an adhesive polymer containing an unsaturated monomer having a total carbon number of 5 or more as a monomer unit, an adhesive polymer containing an alkyl (meth) acrylate having an alkyl group having 4 to 22 carbon atoms as a monomer unit is suitable. Here, (meth) acrylate means acrylate or methacrylate.
粘着性組成物及び粘着性高分子と相容性のあるオイルは、流動パラフィンが好ましい。流動パラフィンを使用すると、皮膚への付着性や貼付時のかぶれの防止効果が優れるようになる。 The oil compatible with the adhesive composition and the adhesive polymer is preferably liquid paraffin. When liquid paraffin is used, the adhesion to the skin and the effect of preventing rash at the time of sticking become excellent.
帯電防止剤として、非イオン性界面活性剤、アニオン性界面活性剤、カチオン性界面活性剤及び両性界面活性剤からなる群より選ばれる少なくとも1つが適している。 As the antistatic agent, at least one selected from the group consisting of a nonionic surfactant, an anionic surfactant, a cationic surfactant and an amphoteric surfactant is suitable.
また、不織布又は織布としては、ポリエステル、ポリエチレン又はポリプロピレンからなるものを用いることができる。また、ポリエステル、ポリエチレン及びポリプロピレンはマイナスに帯電しやすい性質を有しているため、これらの繊維からなる不織布又は織布を用いる場合には、帯電防止剤としてはアニオン性界面活性剤が特に適している。 Moreover, what consists of polyester, polyethylene, or a polypropylene can be used as a nonwoven fabric or a woven fabric. In addition, since polyester, polyethylene, and polypropylene have a property of being easily negatively charged, an anionic surfactant is particularly suitable as an antistatic agent when using a nonwoven fabric or woven fabric made of these fibers. Yes.
本発明によれば、低コスト化が容易であり、粘着剤層と支持体との間に十分な粘着力を確保しながら、皮膚から剥離する際に角質剥離を十分に防止できる貼付剤が提供される。 According to the present invention, there is provided a patch that can be easily reduced in cost and can sufficiently prevent keratin exfoliation when peeling from the skin while ensuring sufficient adhesive force between the adhesive layer and the support. Is done.
以下、本発明の貼付剤の好適な実施形態について詳細に説明する。 Hereinafter, preferred embodiments of the patch of the present invention will be described in detail.
本発明の貼付剤は、粘着性組成物及び粘着性高分子に対しこれらと相容性を有するオイルを所定量含有する粘着剤層と、帯電防止剤を含有し、不織布又は織布からなる支持体とを少なくとも備えるものである。 The patch of the present invention comprises a pressure-sensitive adhesive layer containing a predetermined amount of oil having compatibility with the pressure-sensitive adhesive composition and the pressure-sensitive polymer, an antistatic agent, and a support made of a nonwoven fabric or a woven fabric. And at least a body.
貼付剤は肌に貼り付けて使用するため、粘着性を有する基剤(以下単に「基剤」という場合がある。)が必須成分となる。ここで「粘着性」とは、少なくとも適用温度(肌に貼り付ける温度)においてタックを有していることをいい、当該温度で1Hzにおける弾性率E’が0.1MPa以下(Dahlquist’s criterion)であればよい。基剤としては、このような性質を示すものであれば、1種のみ用いても2種以上を組み合わせて用いてもよい。代表的な基剤としては、エラストマーに粘着付与剤を添加した粘着性組成物と、炭素数5以上の不飽和モノマーをモノマー単位として含む粘着性高分子が挙げられる。 Since the patch is used by being attached to the skin, an adhesive base (hereinafter sometimes simply referred to as “base”) is an essential component. Here, “adhesiveness” means having tack at least at the application temperature (temperature applied to the skin), and the elastic modulus E ′ at 1 Hz at the temperature is 0.1 MPa or less (Dahlquist's criterion). That's fine. As a base, if it shows such a property, you may use only 1 type or may use it in combination of 2 or more type. Typical base materials include an adhesive composition obtained by adding a tackifier to an elastomer, and an adhesive polymer containing an unsaturated monomer having 5 or more carbon atoms as a monomer unit.
粘着性組成物には、天然ゴムに粘着付与剤を加えて粘着性を発現させた粘着性組成物、合成ゴムに粘着付与剤を加えて粘着性を発現させた粘着性組成物、これらのブレンド物等が挙げられるが、処方の容易性から、合成ゴムに粘着付与剤を加えて粘着性を発現させた粘着性組成物が好ましい。このような組成物としてより好ましいのは、熱可塑性エラストマーに粘着付与剤を加えたものであり、特に好ましいのはスチレン系ブロックコポリマーに粘着付与剤を添加した粘着性組成物である。 Adhesive compositions include tackifier compositions in which tackifiers are added to natural rubber to develop tackiness, adhesive compositions in which tackifiers are added to synthetic rubber to develop tackiness, and blends thereof In view of ease of formulation, a pressure-sensitive adhesive composition in which a tackifier is added to a synthetic rubber to develop pressure-sensitive properties is preferable. More preferred as such a composition is a thermoplastic elastomer added with a tackifier, and particularly preferred is a tacky composition obtained by adding a tackifier to a styrenic block copolymer.
スチレン系ブロックコポリマーとしては、スチレン−ブチレン−スチレンブロックコポリマー(SBS)、スチレン−イソプレン−スチレンブロックコポリマー(SIS)、スチレン−エチレン/ブチレン−スチレンブロックコポリマー(SEBS)、スチレン−エチレン/プロピレン−スチレンブロックコポリマー(SEPS)が挙げられる。これらのスチレン系ブロックコポリマーは、リニア(linear)体、ジブロック(diblock)体、ラジアル(radial)体、スター(star)体のいずれの骨格を有していてもよいが、リニア体が好ましい。リニア体は合成経路上ジブロック体を一部含有している場合があるため、ジブロック体を一部含有したリニア体を用いてもよい。また、スチレン系ブロックコポリマーは、1種のみ用いても、2種以上の組合せとして用いてもよい。 Examples of styrenic block copolymers include styrene-butylene-styrene block copolymer (SBS), styrene-isoprene-styrene block copolymer (SIS), styrene-ethylene / butylene-styrene block copolymer (SEBS), and styrene-ethylene / propylene-styrene block. A copolymer (SEPS) is mentioned. These styrenic block copolymers may have a skeleton of a linear body, a diblock body, a radial body, or a star body, but a linear body is preferable. Since the linear body may partially contain the diblock body on the synthesis route, a linear body partially containing the diblock body may be used. Moreover, a styrenic block copolymer may be used alone or in combination of two or more.
スチレン系ブロックコポリマーの具体例としては、カリフレックスTR−1101、TR−1107又はカリフレックスTR−1111(商品名、シェル化学(株)製)、JSR5000又はJSR5002(商品名、日本合成ゴム(株)製)、クインタック3530、3421又は3570C(商品名、日本ゼオン(株)製)、クレイトンD−KX401CS又はD−1107CU(商品名、シェル化学(株)製)、ソルプレン428(商品名、フィリップペトロリアム(株)製)等が挙げられる。 Specific examples of the styrenic block copolymer include Califlex TR-1101, TR-1107 or Califlex TR-1111 (trade name, manufactured by Shell Chemical Co., Ltd.), JSR5000 or JSR5002 (trade name, Nippon Synthetic Rubber Co., Ltd.) Manufactured), Quintac 3530, 3421 or 3570C (trade name, manufactured by Nippon Zeon Co., Ltd.), Kraton D-KX401CS or D-1107CU (trade name, manufactured by Shell Chemical Co., Ltd.), Solprene 428 (trade name, Philippe Petroleum) Etc.).
スチレン系ブロックコポリマーとして好ましいのは、スチレン含有量が10〜30質量%且つジブロック体含有量が40質量%以下のスチレン−イソプレン−スチレンブロックコポリマーであり、特に好ましいのは、スチレン含有量が20〜30質量%且つジブロック体含有量が20質量%以下のスチレン−イソプレン−スチレンブロックコポリマーである。スチレン含有量は20〜25質量%が、ジブロック体含有量は15%以下が特に好ましい。このようなスチレン系ブロックコポリマーを用いることで、皮膚への付着性、角質剥離の防止、支持体と粘着剤層の投錨性のすべてにおいて、より顕著な改善が図れる。 A styrene-based block copolymer is preferably a styrene-isoprene-styrene block copolymer having a styrene content of 10 to 30% by mass and a diblock content of 40% by mass or less, and particularly preferably a styrene content of 20%. A styrene-isoprene-styrene block copolymer having -30% by mass and a diblock content of 20% by mass or less. The styrene content is particularly preferably 20 to 25% by mass, and the diblock content is preferably 15% or less. By using such a styrenic block copolymer, a remarkable improvement can be achieved in all of the adhesion to the skin, prevention of exfoliation of the keratin, and anchoring properties of the support and the pressure-sensitive adhesive layer.
20質量%以上といった高いスチレン含有量や、20質量%以下といった低いジブロック体の含有量は、スチレン系ブロックコポリマーの硬さを向上させ、粘着付与剤と混合して得られる粘着性組成物の硬度をも向上させてしまうが、このような硬めのスチレン系ブロックコポリマーを敢えて使用して、従来用いられているものよりも多い含有量のオイルを用いると、はじめから柔らかいスチレン系ブロックコポリマーを用いそれに少量のオイルを添加した場合に比較して、皮膚への付着性、角質剥離の防止、支持体と粘着剤層の投錨性のすべてにおいて、より顕著な改善が図れる。 A high styrene content such as 20% by mass or more and a low diblock content such as 20% by mass or less improve the hardness of the styrenic block copolymer and can be obtained by mixing with a tackifier. Although the hardness will also be improved, if you use such a hard styrene block copolymer and use oil with a higher content than previously used, a soft styrene block copolymer will be used from the beginning. Compared with the case where a small amount of oil is added thereto, more remarkable improvements can be achieved in all of adhesion to the skin, prevention of exfoliation of the skin, and anchoring properties of the support and the adhesive layer.
粘着付与剤は、エラストマーに粘着性を与えることのできる樹脂であればよく、ロジン、ロジン誘導体、テルペン樹脂、水添テルペン樹脂、ジシクロペンタジエニル系樹脂、脂環族飽和炭化水素樹脂、クマロン樹脂、インデン樹脂等が挙げられる。スチレン−イソプレン−スチレンブロックコポリマーに添加することを考慮すれば、粘着付与剤としては、ロジン又はロジン誘導体をベースとするロジン系樹脂が好ましく、ロジンエステル、水添ロジンエステル、マレイン酸変性ロジンエステル等が好適に用いられ得る。このようなものとしては、ハリエスターL、S又はP(商品名、播磨化学(株)製)、スーパーエステルA−75、又はS−100、パインクリスタルKE−100又はKE−311、エステルガムA、AA−G、H又はHP、アルコンP−70(商品名、荒川化学工業(株)製)、ハリコーンD、フォーラル85、100又は105(商品名、ハーキュリーズ(株)製)等が挙げられ、これらの1種又は2種以上の組合せを使用することができる。 The tackifier may be any resin that can impart tackiness to the elastomer, and includes rosin, rosin derivatives, terpene resins, hydrogenated terpene resins, dicyclopentadienyl resins, alicyclic saturated hydrocarbon resins, coumarone. Examples thereof include resins and indene resins. Considering the addition to the styrene-isoprene-styrene block copolymer, the tackifier is preferably a rosin resin based on rosin or a rosin derivative, such as rosin ester, hydrogenated rosin ester, maleic acid-modified rosin ester, etc. Can be suitably used. As such, Harrier Star L, S or P (trade name, manufactured by Harima Chemical Co., Ltd.), Superester A-75, or S-100, Pine Crystal KE-100 or KE-311, Ester Gum A AA-G, H or HP, Alcon P-70 (trade name, manufactured by Arakawa Chemical Industries, Ltd.), Harikon D, Foral 85, 100 or 105 (trade name, manufactured by Hercules Co., Ltd.), etc. One or a combination of two or more of these can be used.
エラストマーと粘着付与剤との配合比率は、少なくとも適用温度(肌に貼り付ける温度)において、タックが生じるように決定すればよい。典型的な配合量は、エラストマー100質量部に対して粘着付与剤は10〜1000質量部(好ましくは30〜200質量部、より好ましくは30〜150質量部、更に好ましくは40〜120質量部)である。 What is necessary is just to determine the compounding ratio of an elastomer and a tackifier so that tack may arise at least in application temperature (temperature stuck on skin). A typical blending amount is 10 to 1000 parts by mass (preferably 30 to 200 parts by mass, more preferably 30 to 150 parts by mass, still more preferably 40 to 120 parts by mass) with respect to 100 parts by mass of the elastomer. It is.
エラストマーと粘着付与剤からなる粘着性組成物の他、総炭素数5以上の不飽和モノマーをモノマー単位として含む粘着性高分子も基剤として用いることができる。総炭素数5以上の不飽和モノマーをモノマー単位として含む粘着性高分子としては、アルキル基の炭素数が4〜22のアルキル(メタ)アクリレートをモノマー単位として含む粘着性高分子が挙げられ、この高分子は粘着付与剤の添加なしでも粘着性を有している。アルキル基の炭素数が4〜22のアルキル(メタ)アクリレートとしては、ブチル(メタ)アクリレート、ヘキシル(メタ)アクリレート、オクチル(メタ)アクリレート、2−エチルヘキシルアクリレート、デシル(メタ)アクリレート、ドデシル(メタ)アクリレート、テトラデシル(メタ)アクリレート、ヘキサデシル(メタ)アクリレート、オクタデシル(メタ)アクリレート等が挙げられる。なお、総炭素数5以上の不飽和モノマーをモノマー単位として含む粘着性高分子は、1種のみ用いても、2種以上の組合せとして用いてもよい。 In addition to an adhesive composition comprising an elastomer and a tackifier, an adhesive polymer containing an unsaturated monomer having 5 or more carbon atoms as a monomer unit can be used as a base. Examples of the adhesive polymer containing an unsaturated monomer having a total carbon number of 5 or more as a monomer unit include an adhesive polymer containing an alkyl (meth) acrylate having an alkyl group having 4 to 22 carbon atoms as a monomer unit. The polymer is tacky without the addition of a tackifier. Examples of the alkyl (meth) acrylate having 4 to 22 carbon atoms in the alkyl group include butyl (meth) acrylate, hexyl (meth) acrylate, octyl (meth) acrylate, 2-ethylhexyl acrylate, decyl (meth) acrylate, dodecyl (meth) ) Acrylate, tetradecyl (meth) acrylate, hexadecyl (meth) acrylate, octadecyl (meth) acrylate and the like. In addition, the adhesive polymer containing an unsaturated monomer having a total carbon number of 5 or more as a monomer unit may be used alone or in combination of two or more.
上記の粘着性高分子は、アルキル基の炭素数が4〜22のアルキル(メタ)アクリレートのみならず、他のモノマーもモノマー単位として含むコポリマーであることが好ましい。当該他のモノマーとしては単独重合した時のガラス転移温度(DSCで昇温5℃で測定)が50℃以上となるモノマーが好ましい。このようなモノマーとしては、(メタ)アクリル酸、メチル(メタ)アクリレート、イソボルニル(メタ)アクリレート、N−ビニルピロリドン、スチレン等が挙げられる。 The adhesive polymer is preferably a copolymer containing not only an alkyl (meth) acrylate having an alkyl group having 4 to 22 carbon atoms but also other monomers as monomer units. The other monomer is preferably a monomer having a glass transition temperature (measured at 5 ° C. by DSC) of 50 ° C. or higher when homopolymerized. Examples of such a monomer include (meth) acrylic acid, methyl (meth) acrylate, isobornyl (meth) acrylate, N-vinylpyrrolidone, and styrene.
コポリマーの場合のアルキル基の炭素数が4〜22のアルキル(メタ)アクリレートと他のモノマーとの質量比は、フォックス式を用いてガラス転移温度(Tg)が粘着剤層の使用温度(典型的には25℃程度の室温)未満となるように算出するか、重合物の動的粘弾性(周波数1Hz程度)を測定して使用温度(典型的には25℃程度の室温)における貯蔵弾性率が105dyne/cm2のオーダーになるように設定できるが、一般には、前者:後者で質量比90〜98:2〜10である。 In the case of a copolymer, the mass ratio of the alkyl (meth) acrylate having 4 to 22 carbon atoms of the alkyl group and other monomers is determined by using the Fox equation and the glass transition temperature (Tg) is the temperature at which the pressure-sensitive adhesive layer is used (typically Storage modulus at a working temperature (typically a room temperature of about 25 ° C.) by measuring the dynamic viscoelasticity (frequency of about 1 Hz) of the polymer. Can be set to the order of 10 5 dyne / cm 2 , but in general, the mass ratio of the former: the latter is 90 to 98: 2 to 10.
粘着性を有する基剤は複数の成分からなってもよい。例えば、エラストマーと粘着付与剤からなる粘着性組成物の2種又はそれ以上からなるブレンド物、或いは、総炭素数5以上の不飽和モノマーをモノマー単位として含む粘着性高分子の2種又はそれ以上からなるブレンド物であってもよい。更に、エラストマーと粘着付与剤からなる粘着性組成物と、炭素数5以上の不飽和モノマーをモノマー単位として含む粘着性高分子とのブレンド物であってもよい。この場合のブレンド比(質量比)は、前者:後者が10〜90:90〜10が好ましく、20〜80:80〜20がより好ましい。なお、基剤は、上記粘着性組成物と粘着性高分子以外の粘着性成分を含有していてもよい。 The base having adhesiveness may be composed of a plurality of components. For example, a blend comprising two or more adhesive compositions comprising an elastomer and a tackifier, or two or more adhesive polymers comprising unsaturated monomers having a total carbon number of 5 or more as monomer units It may be a blend of Further, it may be a blend of an adhesive composition comprising an elastomer and a tackifier and an adhesive polymer containing an unsaturated monomer having 5 or more carbon atoms as a monomer unit. In this case, the blend ratio (mass ratio) of the former: the latter is preferably 10-90: 90-10, more preferably 20-80: 80-20. In addition, the base may contain an adhesive component other than the adhesive composition and the adhesive polymer.
貼付剤は、上述した粘着性組成物及び粘着性高分子と相容性のあるオイルを含有し、そのオイルの含有量は、粘着性組成物及び粘着性高分子の合計100質量部に対して60〜200質量部である。 The patch contains an oil that is compatible with the above-mentioned adhesive composition and adhesive polymer, and the content of the oil is 100 parts by mass in total of the adhesive composition and the adhesive polymer. It is 60-200 mass parts.
ここでオイルは、上述した粘着性組成物及び粘着性高分子と相容性のあるものであれば特に限定されず、このようなオイルとしては、例えば、常温で液状を呈し、疎水性高分子物質と相溶するものが用いられる。具体的には、エチレングリコール、ジエチレングリコール、トリエチレングリコール、プロピレングリコール、ポリエチレングリコール、ポリプロピレングリコールなどのグリコール類、アーモンド油、オリーブ油、ツバキ油、パーシック油、ラッカセイ油、ひまし油、スクアレン、ラノリンなどの油脂類、酢酸エチル、エチルアルコール、ジメチルスルホキシド、メチルオクチルスルホキシド、ジメチルデシルスルホキシド、メチルオクチルスルホキシド、ジメチルホルムアミド、ジメチルアセチアミド、ジメチルラウリルアミド、ドデシルピロリドン、イソソルビトールのなどの有機溶剤、及び流動パラフィンのような炭化水素類、エトキシ化ステアリルアルコール、グリセリンエステル、フタル酸エステル、ミリスチン酸イソプロピル、ミリスチン酸イソトリデシル、セバシン酸ジエチル、ラウリル酸エチル、N−メチルピロリドン、オレイン酸エチル、オレイン酸、アジピン酸ジイソプロピル、パルミチン酸イソプロピルなどからなる群より選ばれる少なくとも1つを用いることができ、特にこれらの中でも流動パラフィンを用いることが特に好ましい。 Here, the oil is not particularly limited as long as it is compatible with the above-described adhesive composition and adhesive polymer. Examples of such an oil include a liquid at room temperature and a hydrophobic polymer. Those that are compatible with the substance are used. Specifically, glycols such as ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, polyethylene glycol, and polypropylene glycol, and fats such as almond oil, olive oil, camellia oil, persic oil, peanut oil, castor oil, squalene, and lanolin Organic solvents such as ethyl acetate, ethyl alcohol, dimethyl sulfoxide, methyl octyl sulfoxide, dimethyl decyl sulfoxide, methyl octyl sulfoxide, dimethylformamide, dimethyl acetylamide, dimethyl lauryl amide, dodecyl pyrrolidone, isosorbitol, and liquid paraffin Hydrocarbons, ethoxylated stearyl alcohol, glycerin ester, phthalate ester, isopropyl myristate At least one selected from the group consisting of isotridecyl myristate, diethyl sebacate, ethyl laurate, N-methylpyrrolidone, ethyl oleate, oleic acid, diisopropyl adipate, isopropyl palmitate, and the like can be used. Among them, it is particularly preferable to use liquid paraffin.
オイルの含有量は、基剤中に含まれる「エラストマーと粘着付与剤からなる粘着性組成物」及び「総炭素数5以上の不飽和モノマーをモノマー単位として含む粘着性高分子」のみを基準として決定される。例えば、基剤中にこれら以外の化合物(例えば、総炭素が4の不飽和モノマーをモノマー単位として含むポリイソブチレン)が含まれている場合、それが粘着性であってもオイルの含有量の算出の基準とはしない。 The content of oil is based on only “adhesive composition comprising an elastomer and a tackifier” and “adhesive polymer containing an unsaturated monomer having a total carbon number of 5 or more as a monomer unit” contained in the base. It is determined. For example, when the base contains a compound other than these (for example, polyisobutylene containing an unsaturated monomer having a total carbon of 4 as a monomer unit), the oil content is calculated even if it is sticky. It is not a standard.
本発明は、「エラストマーと粘着付与剤からなる粘着性組成物」及び「総炭素数5以上の不飽和モノマーをモノマー単位として含む粘着性高分子」の合計100質量部に対して、60〜200質量部のオイルを用いた時に、粘着剤層と皮膚との間の粘着力を適切にコントロールすることができ、さらに帯電防止剤を含有する支持体に展膏した際には優れた投錨性を発揮するとの新規知見に基づいて成されたものである。オイルの含有量は、上記特性が最適化されることから、65〜185質量部がより好ましく、70〜170質量部が特に好ましい。なお、オイルの含有量が60質量部未満では、粘着剤層と皮膚との間の粘着力が過度に強くなり、貼付剤を皮膚から剥離する際に角質剥離してしまうことがあり、200質量部を超すとべたつきが生じやすく皮膚への粘着力が過度に弱くなると共に、支持体との間の粘着力も過度に弱くなり、支持体に対する投錨性が低下してしまうことがある。支持体との間の粘着力が過度に弱くなると、例えば、貼付剤を皮膚から剥離する際、粘着剤層が凝集破壊し、粘着剤層が皮膚に後残りする不都合が生じる。 The present invention relates to a total of 100 parts by mass of “adhesive composition comprising an elastomer and a tackifier” and “adhesive polymer containing an unsaturated monomer having 5 or more total carbon atoms as a monomer unit”. When using parts by mass of oil, the adhesive force between the adhesive layer and the skin can be controlled appropriately, and when it is spread on a support containing an antistatic agent, it has excellent anchoring properties. It was made based on the new knowledge that it can be demonstrated. The oil content is more preferably 65 to 185 parts by mass and particularly preferably 70 to 170 parts by mass because the above properties are optimized. When the oil content is less than 60 parts by mass, the adhesive force between the adhesive layer and the skin becomes excessively strong, and the exfoliation may occur when the patch is peeled from the skin. If it exceeds the part, stickiness tends to occur, and the adhesive force to the skin becomes excessively weak, and the adhesive force between the support and the support becomes excessively weak, and the anchoring property to the support may be lowered. When the adhesive force between the support and the support is excessively weak, for example, when the patch is peeled from the skin, the adhesive layer is agglomerated and broken, causing the inconvenience that the adhesive layer remains on the skin.
粘着剤層中のその他の配合剤としては、薬物、抗酸化剤、充填剤、架橋剤、防腐剤、紫外線吸収剤、吸収促進剤、その他の各種ポリマー(粘着性又は非粘着性)等が挙げられる。 Examples of other compounding agents in the pressure-sensitive adhesive layer include drugs, antioxidants, fillers, crosslinking agents, preservatives, ultraviolet absorbers, absorption accelerators, and other various polymers (adhesive or non-adhesive). It is done.
本発明の貼付剤の粘着剤層に含有される薬物としては、特に限定されず、例えば、アセトアミノフェノン、フェナセチン、メフェナム酸、ジクロフェナクナトリウム、フルフェナム酸、アスピリン、サリチル酸ナトリウム、サリチル酸メチル、サリチル酸グリコール、アミノピリン、アルクロフェナク、イブプロフェン、ナプロキセン、フルルビプロフェン、ケトプロフェン、アンフェナクナトリウム、メピリゾール、インドメタシン、ピロキシカム、フェルビナク等の消炎鎮痛剤;ヒドロコルチゾン、トリアムシノロン、デキサメタゾン、プレドニゾロン等のステロイド系抗炎症剤;塩酸ジルチアゼム、四硝酸ペンタエリスリトール、硝酸イソソルビド、タラジピル、ニコランジル、ニトログリセリン、乳酸プレニラミン、モルシドミン、亜硝酸アルミ、塩酸トラゾリン、ニフェジピン等の血管拡張剤;塩酸プロカインアミド、塩酸リドカイン、塩酸プロプラノロール、塩酸アルプレノロール、アテノロール、ナドロール、酒石酸メトプロロール、アジマリン、ジソピラミド、塩酸メキシレチン等の不整脈用剤;塩酸エカラジン、インダパミド、塩酸クロニジン、塩酸ブニトロロール、塩酸ラベタロール、カプトプリル、酢酸グアナベンズ、メブタメート、硫酸ベタニジン等の血圧降下剤;クエン酸カルベタペンタン、クロペラスチン、タンニン酸オキセラジン、塩酸クロプチノール、塩酸クロフェダノール、塩酸ノスカピン、塩酸エフェドリン、塩酸イソプロテレノール、塩酸クロリプレナリン、塩酸メトキシフェナミン、塩酸プロカテロール、塩酸ツロブテロール、塩酸クレンプテロール、フマル酸ケトチフェン等の鎮該去痰剤;シクロフォスファミド、フルオロウラシル、デガフール、マイトマイシンC、塩酸プロカルバジン、ドキシフルリジン、ラニムスチン等の抗悪性腫瘍剤;アミノ安息香酸エチル、塩酸テトラカイン、塩酸ブロカイン、塩酸ジブカイン、塩酸オキシブプロカイン、塩酸プロピトカイン等の局所麻酔剤;プロピルチオウラシル、チアマゾール、酢酸メテロノン、エストラジオール、エストリオール、プロゲステロン等のホルモン剤;塩酸ジフェンヒドラミン、マレイン酸クロルフェニラミン、プロメタジン、塩酸ジプロヘプタジン、塩酸ジフェニルピラリン等の抗ヒスタミン剤;ワルファリンカリウム、塩酸チクロピジン等の血液凝固阻止剤;臭化メチルアトロピン、スコポラミン等の鎮痙剤;チオペンタールナトリウム、ペントバルビタールナトリウム等の全身麻酔剤;ブロムワレニル尿素、アモバルビタール、フェノバルビタール等の催眠・鎮痛剤;フェニトインナトリウム等の抗癲癇剤;塩酸メタンフェタミン等の興奮剤・覚醒剤;塩酸ジフェンドール、メシル酸ベタヒスチン等の鎮暈剤;塩酸クロルプロマジン、チオリダジン、メプロバメート、塩酸イミプラミン、クロルジアゼポキシド、ジアゼパム等の精神神経用剤;塩酸スキサメトニウム、塩酸エペリゾン等の骨格筋弛緩剤;臭化ネオスチグミン、塩化ベタネコール等の自律神経用剤;塩酸アマンタジン等の抗パーキンソン剤;ヒドロフルメチアジド、イソソルビド、フロセミド等の利尿剤;塩酸フェニレフリン等の血管収縮剤;臭化ロベリン、ジモルホラミン、塩酸ナロキソン等の呼吸促進剤;臭化グリコピロニウム、プログルミド、塩酸セトラキサート、シメチジン、スピゾフロン等の消化性潰瘍治療剤;ウルソデスオキシコール酸、オサルミド等の利胆剤;ヘキサミン、スパルティン、ジノプロスト、塩酸リトドリン等の泌尿生殖器及び肛門用剤;サリチル酸、シクロピロクスオラミン、塩酸コロコナゾール等の寄生性皮膚疾患用剤;尿素等の皮膚軟化剤;カルシトリオール、塩酸チアミン、リン酸リボフラピンナトリウム、塩酸ピリドキシン、ニコチン酸アミド、パンテノール、アスコルビン酸等のビタミン剤;塩化カルシウム、ヨウ化カリウム、ヨウ化ナトリウム等の無機質製剤;エタンシラート剤の止血剤;チオプロニン等の肝臓疾患用剤;シアナミド等の習慣性中毒用剤;コルヒチン、プロベネシド、スルフィンピラゾン等の通風治療剤;トルブタミド、クロルプロパミド、グリミジンナトリウム、グリプゾール、塩酸プホルミン、インスリン等の糖尿病用剤;ベンジルペニシリンカリウム、プロピシリンカリウム、クロキサシリンナトリウム、アンピシリンナトリウム、塩酸バカンピリシン、カルベニシリンナトリウム、セファロリジン、セフォキシチンナトリウム、エリスロマイシン、クロラムフェニコール、テトラサイクリン、硫酸カナマイシン、サイクロセリン等の抗生物質;イソシアニド、ピラジナミド、エチオナミド等の化学療法剤;塩酸モルヒネ、リン酸コディン、塩酸コカイン、塩酸ペチジン、クエン酸フェンタニル等の麻薬等が挙げられる。 The drug contained in the adhesive layer of the patch of the present invention is not particularly limited, for example, acetaminophenone, phenacetin, mefenamic acid, diclofenac sodium, flufenamic acid, aspirin, sodium salicylate, methyl salicylate, glycol salicylate, Antipyretic analgesics such as aminopyrine, alclofenac, ibuprofen, naproxen, flurbiprofen, ketoprofen, sodium amphenac, mepyrizole, indomethacin, piroxicam, felbinac; steroidal anti-inflammatory drugs such as hydrocortisone, triamcinolone, dexamethasone, prednisolone hydrochloride, diltiazem hydrochloride Pentaerythritol tetranitrate, isosorbide nitrate, taradipyl, nicorandil, nitroglycerin, prenylamine lactate, molsidomine, Vasodilators such as aluminum nitrate, trazoline hydrochloride, nifedipine; arrhythmic agents such as procainamide hydrochloride, lidocaine hydrochloride, propranolol hydrochloride, alprenolol hydrochloride, atenolol, nadolol, metoprolol tartrate, ajmarin, disopyramide, mexiletine hydrochloride; ecarazine hydrochloride, Antihypertensive agents such as indapamide, clonidine hydrochloride, bunitrolol hydrochloride, labetalol hydrochloride, captopril, guanabenz acetate, mebutamate, betanidine sulfate; carbetapentane citrate, cloperastine, oxerazine tannate, cloptinol hydrochloride, clofedanol hydrochloride, noscapine hydrochloride, hydrochloride Ephedrine, isoproterenol hydrochloride, chloriprenaline hydrochloride, methoxyphenamine hydrochloride, procaterol hydrochloride, tulobuterol hydrochloride, Antifungal agents such as pterol and ketotifen fumarate; antineoplastic agents such as cyclophosphamide, fluorouracil, degafur, mitomycin C, procarbazine hydrochloride, doxyfluridine, ranimustine; ethyl aminobenzoate, tetracaine hydrochloride, brocaine hydrochloride, hydrochloric acid Local anesthetics such as dibucaine, oxybuprocaine hydrochloride, propitocaine hydrochloride; hormonal agents such as propylthiouracil, thiamazole, metellonone acetate, estradiol, estriol, progesterone; diphenhydramine hydrochloride, chlorpheniramine maleate, promethazine, diproheptazine hydrochloride, hydrochloric acid Antihistamines such as diphenylpyraline; anticoagulants such as warfarin potassium and ticlopidine hydrochloride; antispasmodic agents such as methyl atropine bromide and scopolamine General anesthetics such as sodium thiopental and sodium pentobarbital; hypnotics and analgesics such as bromvalenyl urea, amobarbital and phenobarbital; antidepressants such as sodium phenytoin; stimulants and stimulants such as methamphetamine hydrochloride; difendol hydrochloride and betahistine mesylate Antipruritic agents such as: Chlorpromazine hydrochloride, thioridazine, meprobamate, imipramine hydrochloride, chlordiazepoxide, diazepam and other neuropsychiatric agents; Skeletal muscle relaxants such as squismethonium hydrochloride and eperisone hydrochloride; Autonomic nerve agents such as neostigmine bromide and betanecol chloride; Antiparkinsonian agents such as amantadine hydrochloride; diuretics such as hydroflumethiazide, isosorbide, furosemide; vasoconstrictors such as phenylephrine hydrochloride; lobeline bromide, dimorpholamine, sodium chloride Respiratory stimulants such as roxone; peptic ulcers such as glycopyrronium bromide, proglumide, cetraxate hydrochloride, cimetidine, spizofuron; and other antibacterial agents such as ursodeoxycholic acid and osalmid; Urogenital and anal preparations such as: salicylic acid, ciclopirox olamine, colconazole hydrochloride and other parasitic skin disease agents; urea and other emollients; calcitriol, thiamine hydrochloride, riboflavin sodium phosphate, pyridoxine hydrochloride, Vitamins such as nicotinamide, panthenol, and ascorbic acid; inorganic preparations such as calcium chloride, potassium iodide, and sodium iodide; hemostatic agents of ethanesylate; agents for liver diseases such as thiopronin; for addictive poisoning such as cyanamide Agents: colchicine, probene Ventilation treatments such as sulfinpyrazone, sulfinpyrazone; Tolbutamide, Chlorpropamide, Glymidine sodium, Glypsol, Puformin hydrochloride, Insulin, etc .; Benzylpenicillin potassium, propicillin potassium, cloxacillin sodium, ampicillin sodium, hydrochloric acid Antibiotics such as bacampyricin, sodium carbenicillin, cephaloridine, cefoxitin sodium, erythromycin, chloramphenicol, tetracycline, kanamycin sulfate, cycloserine; chemotherapeutic agents such as isocyanide, pyrazinamide, etionamide; morphine hydrochloride, codin phosphate Narcotics such as cocaine hydrochloride, pethidine hydrochloride, fentanyl citrate, and the like.
抗酸化剤としては、トコフェロール及びそのエステル誘導体、アスコルビン酸、アスコルビン酸ステアリン酸エステル、ノルジヒドログアヤレチン酸、ジブチルヒドロキシトルエン、ブチルヒドロキシアソニール等が好ましい。 As the antioxidant, tocopherol and its ester derivatives, ascorbic acid, ascorbic acid stearate, nordihydroguaiaretic acid, dibutylhydroxytoluene, butylhydroxyasonyl and the like are preferable.
充填剤としては、炭酸カルシウム、炭酸マグネシウム、ケイ酸塩(例えば、ケイ酸アルミニウム、ケイ酸マグネシウム等)、ケイ酸、硫酸バリウム、硫酸カルシウム、亜鉛酸カルシウム、酸化亜鉛、酸化チタン、ステアリン酸亜鉛等が好ましい。 Examples of the filler include calcium carbonate, magnesium carbonate, silicate (eg, aluminum silicate, magnesium silicate, etc.), silicic acid, barium sulfate, calcium sulfate, calcium zincate, zinc oxide, titanium oxide, zinc stearate, etc. Is preferred.
架橋剤としては、熱硬化性樹脂(アミノ樹脂、フェノール樹脂、エポキシ樹脂、アルキド樹脂、不飽和ポリエステル等)、イソシアネート化合物、ブロックイソシアネート化合物のような有機系架橋剤や、金属又は金属化合物のような無機系架橋剤が好ましい。 Examples of the crosslinking agent include thermosetting resins (amino resins, phenol resins, epoxy resins, alkyd resins, unsaturated polyesters, etc.), isocyanate compounds, organic crosslinking agents such as blocked isocyanate compounds, and metals or metal compounds. Inorganic crosslinking agents are preferred.
防腐剤としては、パラオキシ安息香酸エチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸ブチル等が好ましい。 As the preservative, ethyl paraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate and the like are preferable.
紫外線吸収剤としては、p−アミノ安息香酸誘導体、アントラニル酸誘導体、サリチル酸誘導体、クマリン誘導体、アミン酸系化合物、イミダゾリン誘導体、ピリジン誘導体、ジオキサン誘導体等が好ましい。 As the ultraviolet absorber, p-aminobenzoic acid derivatives, anthranilic acid derivatives, salicylic acid derivatives, coumarin derivatives, amine acid compounds, imidazoline derivatives, pyridine derivatives, dioxane derivatives and the like are preferable.
吸収促進剤としては、d−リモネン等のテルペン油、グリセリンモノラウレート、グリセリンモノオレート、セバシン酸ジエチル等の脂肪酸エステル、エイゾン、ピロチオデカン、オレイン酸、ラウリン酸、ミリスチン酸等の脂肪酸又はその誘導体等が挙げられる。 Absorption accelerators include terpene oils such as d-limonene, fatty acid esters such as glycerol monolaurate, glycerol monooleate, and diethyl sebacate, fatty acids such as azone, pyrothiodecane, oleic acid, lauric acid, myristic acid, and derivatives thereof. Is mentioned.
その他のポリマーとしては、総炭素数2〜4の不飽和モノマーをモノマー単位として含む高分子、例えばポリイソブチレン等が挙げられ、当該高分子は、粘着性でも非粘着性でもよい。このようなポリマー成分を添加する場合は、この含有量を貼付剤全質量基準で5〜15質量%とし、粘着性を有する基剤及びオイルの合計重量を同基準で80〜90質量%とすることが好ましい。 Examples of the other polymer include a polymer containing an unsaturated monomer having 2 to 4 carbon atoms as a monomer unit, such as polyisobutylene, and the polymer may be adhesive or non-adhesive. When such a polymer component is added, the content is 5 to 15% by mass based on the total mass of the patch, and the total weight of the adhesive base and oil is 80 to 90% by mass based on the same standard. It is preferable.
本発明の貼付剤は、上述した粘着剤層を支持体に展膏して構成されるが、この場合、支持体上に50〜300g/m2の塗膏量となるように粘着剤層を形成することが好ましい。より好ましくは60〜250g/m2、さらに好ましくは80〜210g/m2である。 The patch of the present invention is constituted by plastering the above-mentioned pressure-sensitive adhesive layer on a support. In this case, the pressure-sensitive adhesive layer is applied on the support so that the coating amount is 50 to 300 g / m 2. It is preferable to form. More preferably 60~250g / m 2, more preferably from 80~210g / m 2.
本発明の貼付剤を構成する支持体としては、支持体に静電気が蓄積することを防止するため、並びに、粘着剤層との良好な投錨性のため、帯電防止剤を含む不織布又は織布を用いる。 As the support constituting the patch of the present invention, a non-woven fabric or a woven fabric containing an antistatic agent is used for preventing static electricity from accumulating on the support and for good anchoring properties with the adhesive layer. Use.
支持体は単層構造に限られず、積層構造であってもよい。例えば、異なる材料からなる複数の不織布又は織布を積層した構造であっても、プラスチックフィルム、金属箔等と不織布又は織布とを積層した構造であってもよい。不織布又は織布は、通常貼付剤の支持体に用いる材料により形成することができるが、好ましい例としては、ポリエステル系、ポリエチレン系、ポリプロピレン系の材料を1種又は2種以上組み合わせてなる不織布又は織布が挙げられ、中でも薬物との相互作用が少ないポリエステル系のポリエチレンテレフタレートからなる織布がより好ましい。 The support is not limited to a single layer structure, and may be a laminated structure. For example, it may be a structure in which a plurality of nonwoven fabrics or woven fabrics made of different materials are laminated, or a structure in which a plastic film, a metal foil or the like and a nonwoven fabric or woven fabric are laminated. The non-woven fabric or woven fabric can be formed of a material usually used for the support of the patch, but as a preferred example, a non-woven fabric or a combination of one or more polyester-based, polyethylene-based, or polypropylene-based materials A woven fabric is mentioned, and among them, a woven fabric made of polyester-based polyethylene terephthalate that has little interaction with drugs is more preferable.
さらに織布としては、粘着剤層と優れた投錨性を有することができれば限定されないが、捲縮加工により施工されたマルチフィラメント糸を複数段の両面メリヤス編みによるポリエステル系の編み布であれば、さらに好ましい投錨性及び貼付時の使用感を得ることができる。 Furthermore, the woven fabric is not limited as long as it has an adhesive layer and excellent anchoring properties, but if it is a polyester-based knitted fabric by multi-stage double-sided knitting multifilament yarn constructed by crimping, Furthermore, a preferable anchoring property and a feeling of use at the time of sticking can be obtained.
すなわち、かかる編み方により編まれた編み布に下記に示す帯電防止剤を含有する支持体を貼付剤に用いた場合は、粘着剤層の一部が支持体内部に浸透するため、さらに良好な投錨性を有することになる。 That is, when a support containing the antistatic agent shown below is used for the patch on a knitted fabric knitted by such a knitting method, a part of the pressure-sensitive adhesive layer penetrates into the inside of the support, which is even better. It will have a throwing ability.
また、上記よりポリエチレンテレフタレート織布を用いる場合は、その目付けは80〜150g/m2であることが好ましい。かかる範囲であれば、粘着剤層を織布に塗布する際に粘着剤層が織布の網目を通じて染み出すことが無く、かつ粘着剤層との投錨性を維持することができる。またポリエチレンテレフタレート織布は、縦方向(長軸方向)モジュラスが2〜12N/5cm、横方向(短軸方向)モジュラスが2〜8N/5cmであることが好ましい(測定法:JIS L 1018)。2N/5cmより低いモジュラスであると粘着剤層を塗布する際に織布が伸びて網目に粘着剤層が染み込み、貼付剤としての機能を低下させる傾向があり、また、12N/5cm(縦方向)、又は8N/5cm(横方向)より高いモジュラスであると伸縮性が劣り、体の屈曲部へ適用した際に皮膚の伸張に追随しなくなる傾向がある。 Moreover, when using a polyethylene terephthalate woven fabric from the above, it is preferable that the fabric weight is 80-150 g / m < 2 >. If it is this range, when apply | coating an adhesive layer to a woven fabric, an adhesive layer does not ooze out through the mesh | network of a woven fabric, and anchorage with an adhesive layer can be maintained. The polyethylene terephthalate woven fabric preferably has a longitudinal (major axis) modulus of 2 to 12 N / 5 cm and a transverse (minor axis direction) modulus of 2 to 8 N / 5 cm (measurement method: JIS L 1018). When the adhesive layer has a modulus lower than 2 N / 5 cm, the woven fabric is stretched when the adhesive layer is applied, and the adhesive layer penetrates into the mesh, and the function as a patch tends to be reduced. In addition, 12 N / 5 cm (longitudinal direction) ) Or a modulus higher than 8 N / 5 cm (lateral direction), the stretchability is poor, and when applied to a bent part of the body, there is a tendency not to follow the stretching of the skin.
支持体が含有する帯電防止剤としては、本発明の効果を有するものであれば特に限定はされないが、界面活性剤を帯電防止剤として用いるのが好ましい。界面活性剤は、アニオン性界面活性剤、カチオン性界面活性剤、非イオン性界面活性剤および両性界面活性剤のいずれでもよく、これらの1種又は2種以上を併用してもよい。界面活性剤としては支持体の材質との関係(例えば、ポリエステルはマイナスに帯電しやすい)から、アニオン性界面活性剤が特に好ましい。支持体が含有する帯電防止剤の含有量は、高い帯電防止効果及び支持体と粘着剤層との高い投錨性を得るために、支持体の全質量基準で
0.05〜2質量%であることが好ましく、0.05〜1質量%であることがより好ましい。
The antistatic agent contained in the support is not particularly limited as long as it has the effects of the present invention, but a surfactant is preferably used as the antistatic agent. The surfactant may be any of an anionic surfactant, a cationic surfactant, a nonionic surfactant and an amphoteric surfactant, and one or more of these may be used in combination. As the surfactant, an anionic surfactant is particularly preferable because of its relationship with the material of the support (for example, polyester is easily negatively charged). In order to obtain a high antistatic effect and a high anchoring property between the support and the pressure-sensitive adhesive layer, the content of the antistatic agent contained in the support is 0.05 to 2% by mass based on the total mass of the support. It is preferable that it is 0.05-1 mass%.
アニオン性界面活性剤は特に限定されず、例えば脂肪酸塩(ステアリン酸ナトリウム、ラウリン酸ナトリウム、ラウリン酸トリエタノールアミン等)、アルキルベンゼンスルホン酸塩(ドデシルベンゼンスルホン酸ナトリウム等)、アルキルスルホン酸塩、α−オレフィンスルホン酸塩、モノアルキルスルホコハク酸塩、ジアルキルスルホコハク酸塩、α−スルホン化脂肪酸塩、アシルメチルタウリン塩、N−メチル−N−アルキルタウリン塩、ポリオキシエチレンアルキルエーテル硫酸塩、ポリオキシエチレンアルキルフェニルエーテル硫酸塩、アルキルリン酸塩、ポリオキシエチレンアルキルエーテルリン酸塩、ポリオキシエチレンアルキルフェニルエーテルリン酸塩、N−アシルアミノ酸塩、N−アシル−N−アルキルアミノ酸塩、ポリオキシエチレンアルキルフェニルエーテルスルホン酸塩、アルキルナフタレンスルホン酸塩、アルキルジフェニルエーテルジスルホン酸、ポリオキシエチレンアルキルエーテルスルホコハク酸塩、ポリオキシエチレンアルキルエーテル酢酸塩、アルケニルコハク酸塩等、およびそれらの酸が挙げられる。これらのアニオン性界面活性剤は単独で用いても2種以上を併用してもよい。 The anionic surfactant is not particularly limited, and examples thereof include fatty acid salts (such as sodium stearate, sodium laurate, triethanolamine laurate), alkylbenzene sulfonates (such as sodium dodecylbenzene sulfonate), alkyl sulfonates, α -Olefin sulfonate, monoalkyl sulfosuccinate, dialkyl sulfosuccinate, α-sulfonated fatty acid salt, acylmethyl taurate, N-methyl-N-alkyl taurate, polyoxyethylene alkyl ether sulfate, polyoxyethylene Alkylphenyl ether sulfate, alkyl phosphate, polyoxyethylene alkyl ether phosphate, polyoxyethylene alkylphenyl ether phosphate, N-acyl amino acid salt, N-acyl-N-alkyl amino acid salt, poly Examples include oxyethylene alkylphenyl ether sulfonate, alkyl naphthalene sulfonate, alkyl diphenyl ether disulfonic acid, polyoxyethylene alkyl ether sulfosuccinate, polyoxyethylene alkyl ether acetate, alkenyl succinate, and their acids. . These anionic surfactants may be used alone or in combination of two or more.
カチオン性界面活性剤は特に限定されず、例えば長鎖アルキル短鎖トリアルキルアンモニウム塩(ラウリルトリメチルアンモニウムクロリド、ミリスチルトリメチルアンモニウムクロリド、パルミチルトリメチルアンモニウムクロリド、ステアリルトリメチルアンモニウムクロリド)、長鎖ジアルキル短鎖ジアルクルアンモニウム塩、(ジステリアリルジメチルアンモニウムクロリド)、アルキルピリジニウム塩(塩化ミリスチルピリジニウム、塩化セチルピリジニウム、塩化ステアリルピリジニウム等)、アルキルイミダゾリニウム塩(1,1−ジメチル−2−ヘキサデシルイミダゾリニウムクロライド等)、ベンジル長鎖アルキル短鎖ジアルキルアンモニウム塩(塩化ベンザルコニウム、塩化ベンゼトニウム等)等、およびそれらの誘導体が挙げられる。これらのカチオン性界面活性剤は単独で用いても、2種以上を併用してもよい。 The cationic surfactant is not particularly limited. For example, a long-chain alkyl short-chain trialkylammonium salt (lauryltrimethylammonium chloride, myristyltrimethylammonium chloride, palmityltrimethylammonium chloride, stearyltrimethylammonium chloride), long-chain dialkyl short-chain dia Lucur ammonium salt, (distearyl allyl ammonium chloride), alkyl pyridinium salt (myristyl pyridinium chloride, cetyl pyridinium chloride, stearyl pyridinium chloride, etc.), alkyl imidazolinium salt (1,1-dimethyl-2-hexadecyl imidazolinium) Chloride), benzyl long-chain alkyl short-chain dialkylammonium salts (benzalkonium chloride, benzethonium chloride, etc.), and their derivatives Is mentioned. These cationic surfactants may be used alone or in combination of two or more.
非イオン性界面活性剤は特に限定されず、例えばグリセリン脂肪酸エステルおよびそのアルキレングリコール付加物、ポリグリセリン脂肪酸エステルおよびそのアルキレングリコール付加物、プロピレングリコール脂肪酸エステルおよびそのアルキレングリコール付加物、プロピレングリコール脂肪酸エステルおよびそのアルキレングリコール付加物、ソルビタン脂肪酸エステルおよびそのアルキレングリコール付加物、ソルビトールの脂肪酸エステルおよびそのアルキレングリコール付加物、ポリアルキレングリコール脂肪酸エステル、蔗糖脂肪酸エステル、ポリオキシアルキレンアルキルエーテル、グリセリンアルキルエーテル、ポリオキシエチレンアルキルフェニルエーテル、ポリオキシエチレン硬化ヒマシ油、ラノリンのアルキレングリコール付加物、ポリオキシアルキレンアルキル共変性シリコーン、ポリエーテル変性シリコーン等が挙げられる。これらの非イオン性界面活性剤は単独で用いても2種以上を併用してもよい。 The nonionic surfactant is not particularly limited, and for example, glycerin fatty acid ester and its alkylene glycol adduct, polyglycerin fatty acid ester and its alkylene glycol adduct, propylene glycol fatty acid ester and its alkylene glycol adduct, propylene glycol fatty acid ester and Its alkylene glycol adduct, sorbitan fatty acid ester and its alkylene glycol adduct, sorbitol fatty acid ester and its alkylene glycol adduct, polyalkylene glycol fatty acid ester, sucrose fatty acid ester, polyoxyalkylene alkyl ether, glycerin alkyl ether, polyoxyethylene Alkyl phenyl ether, polyoxyethylene hydrogenated castor oil, lanolin alkylene Recall adducts, polyoxyalkylene alkyl co-modified silicone, polyether-modified silicone, and the like. These nonionic surfactants may be used alone or in combination of two or more.
両性界面活性剤は特に限定されず、例えば酢酸ベタイン型両性界面活性剤(ラウリルジメチルアミノ酢酸ベタイン、ステアリルジメチルアミノ酢酸ベタイン、ミリスチルアミノ酢酸ベタイン、ラウリン酸アミドプロピル酢酸ベタイン等)、アルキルアミンオキサイド型両性界面活性剤(アルキルジメチルアミンオキサイド等)、イミダゾリン型両面活性剤(2−アルキル−N−カルボキシメチル−N−ヒドロキシエチルイミダゾリニウムベタイン、2−コココイル−N−カルボキシメチル−N−ヒドロキシメチルイミダゾリニウムベタイン、2−ラウリル−N−カルボキシメチル−N−ヒドロキシエチルイミダゾリニウムベタイン等)、スルホベタイン型両性界面活性剤等が挙げられる。これらの両性界面活性剤は単独で用いても、2種以上を併用してもよい。 The amphoteric surfactant is not particularly limited. For example, betaine acetate type amphoteric surfactant (lauryldimethylaminoacetic acid betaine, stearyldimethylaminoacetic acid betaine, myristylaminoacetic acid betaine, lauric acid amidopropylacetic acid betaine, etc.), alkylamine oxide type amphoteric Surfactant (alkyldimethylamine oxide, etc.), imidazoline type double-sided activator (2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine, 2-cococoyl-N-carboxymethyl-N-hydroxymethyl imidazole) Nitrobetaine, 2-lauryl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, etc.), sulfobetaine-type amphoteric surfactants and the like. These amphoteric surfactants may be used alone or in combination of two or more.
上記帯電防止剤を含む不織布又は織布からなる支持体は、JIS L 1094に規定の帯電性試験後の帯電圧が−50〜−4000Vであるものが好ましく、−100〜−3000Vであるものがより好ましく、−500〜−3000Vであるものが更に好ましい。なお、帯電性試験後の帯電圧が−4000Vより小さい(帯電圧の絶対値が大きい)支持体では、静電気により皺が発生しやすくなるだけでなく、粘着剤層を展膏した際の投錨性が低下し、展膏後に粘着剤層が支持体から剥離したり、貼付剤を患部に適用した後に皮膚に粘着剤層が後残りする傾向がある。一方、帯電性試験後の帯電圧が−50Vより大きい(帯電圧の絶対値が小さい)支持体では、粘着剤層の投錨性が低下する傾向がある。すなわち、帯電性試験後の帯電圧が上記範囲にある支持体を用いることにより、静電気による製造効率の低下を防止できるだけでなく、粘着剤層と支持体の投錨性をより好ましい状態とすることが可能となる。 The support made of a nonwoven fabric or a woven fabric containing the antistatic agent preferably has a charged voltage of −50 to −4000 V after the chargeability test specified in JIS L 1094, and preferably has a voltage of −100 to −3000 V. More preferably, it is -500 to -3000V. In addition, in the support whose charging voltage after the charging test is smaller than −4000 V (absolute voltage has a large absolute value), not only is the wrinkle easily generated by static electricity, but also the anchoring property when the adhesive layer is spread. There is a tendency that the adhesive layer peels off from the support after spreading, or the adhesive layer remains on the skin after the patch is applied to the affected area. On the other hand, in the support having a charged voltage after the chargeability test of greater than −50 V (the absolute value of the charged voltage is small), the anchoring property of the pressure-sensitive adhesive layer tends to decrease. That is, by using a support in which the charged voltage after the chargeability test is in the above range, not only can the production efficiency be reduced due to static electricity, but also the anchoring property of the pressure-sensitive adhesive layer and the support can be made more favorable. It becomes possible.
界面活性剤を不織布又は織布に含有させる方法としては、衣類等の繊維に帯電防止剤を付与する公知の方法を用いることができる。例えば、界面活性剤を含有する水溶液に不織布又は織布を浸し、界面活性剤を不織布又は織布に吸着させた後、これを乾燥させればよい。 As a method for incorporating the surfactant into the nonwoven fabric or woven fabric, a known method for imparting an antistatic agent to fibers such as clothing can be used. For example, the nonwoven fabric or woven fabric is immersed in an aqueous solution containing a surfactant, and the surfactant is adsorbed on the nonwoven fabric or woven fabric, and then dried.
本発明を以下の実施例に基づいてさらに詳細に説明するが、本発明はこれらの実施例に限定されるものではない。 The present invention will be described in more detail based on the following examples, but the present invention is not limited to these examples.
<実施例1>
表1に示す各成分をそれぞれ所定量秤量し、これらを混合して膏体を得た。
<Example 1>
A predetermined amount of each component shown in Table 1 was weighed and mixed to obtain a paste.
一方、ポリエチレンテレフタレート織布(目付け100g/m2、縦モジュラス10N/5cm、横モジュラス5N/5cm)にアニオン性界面活性剤(デレクトールKC:明成化学工業(株)製)を固形分換算で全質量に対し約0.1質量%吸着させた。このようにして得られた支持体の帯電性試験後の帯電圧は−2000Vであった。なお、帯電性試験は、JIS L 1094に従って実施し、摩擦布として木綿を用い、20℃、湿度40%RHの環境で試験した。 Meanwhile, polyethylene terephthalate woven fabric (100 g / m 2 in basis weight, longitudinal modulus 10 N / 5 cm, lateral modulus 5 N / 5 cm) and anionic surfactant (Delectol KC: manufactured by Meisei Chemical Co., Ltd.) in terms of solid content About 0.1% by mass was adsorbed. The charged voltage after the chargeability test of the support thus obtained was −2000V. The chargeability test was carried out in accordance with JIS L 1094, using cotton as a friction cloth and tested in an environment of 20 ° C. and humidity 40% RH.
そして、支持体の片面に上記膏体をホットメルト法により展膏して粘着剤層を形成した後、所望の大きさに裁断してテープ状の貼付剤を得た。
<実施例2>
表2に示す各成分をそれぞれ所定量秤量し、これらを実施例1と同様の条件で混合し、膏体を得た。
<Example 2>
A predetermined amount of each component shown in Table 2 was weighed and mixed under the same conditions as in Example 1 to obtain a paste.
一方、ポリエチレンテレフタレート織布(目付け80g/m2、縦モジュラス4N/5cm、横モジュラス3N/5cm)にアニオン性界面活性剤(ナイスポールPR−99:日華化学(株)製)を固形分換算で全質量に対し約0.5質量%吸着させた。このようにして得られた支持体の帯電性試験後の帯電圧は−1000Vであった。なお、帯電性試験は実施例1と同様にして実施した。 On the other hand, an anionic surfactant (Nicepol PR-99: manufactured by Nikka Chemical Co., Ltd.) is converted into solid content on a polyethylene terephthalate woven fabric (weighing 80 g / m 2 , longitudinal modulus 4 N / 5 cm, transverse modulus 3 N / 5 cm). And about 0.5% by mass was adsorbed with respect to the total mass. The charged voltage after the chargeability test of the support thus obtained was -1000V. The chargeability test was performed in the same manner as in Example 1.
そして、支持体の片面に上記膏体をホットメルト法により展膏して粘着剤層を形成した後、所望の大きさに裁断してテープ状の貼付剤を得た。
<実施例3>
表3に示す各成分をそれぞれ所定量秤量し、これらを実施例1と同様の条件で混合し、膏体を得た。
<Example 3>
A predetermined amount of each component shown in Table 3 was weighed and mixed under the same conditions as in Example 1 to obtain a paste.
一方、ポリエチレンテレフタレート織布(目付け140g/m2、縦モジュラス12N/5cm、横モジュラス7N/5cm)にアニオン性界面活性剤(デレクトールKC:明成化学工業(株)製)を固形分換算で全質量に対し約0.05質量%吸着させた。このようにして得られた支持体の帯電性試験後の帯電圧は−3900Vであった。なお、帯電性試験は実施例1と同様にして実施した。支持体の片面に上記膏体をホットメルト法により展膏して粘着剤層を形成した後、所望の大きさに裁断してテープ状の貼付剤を得た。
<実施例4>
表4に示す各成分をそれぞれ所定量秤量し、これらを実施例1と同様の条件で混合し、膏体を得た。
<Example 4>
A predetermined amount of each component shown in Table 4 was weighed and mixed under the same conditions as in Example 1 to obtain a paste.
一方、ポリエチレンテレフタレート織布(目付け120g/m2、縦モジュラス8N/5cm、横モジュラス4N/5cm)に非イオン性界面活性剤(ナイスポ−ルEF−26:日華化学(株)製)を固形分換算で全質量に対し約0.1質量%吸着させた。このようにして得られた支持体の帯電性試験後の帯電圧は−3000Vであった。なお、帯電性試験は実施例1と同様にして実施した。 On the other hand, a nonionic surfactant (Nice Pol EF-26: manufactured by Nikka Chemical Co., Ltd.) is solidified on a polyethylene terephthalate woven fabric (weighing 120 g / m 2 , longitudinal modulus 8 N / 5 cm, transverse modulus 4 N / 5 cm). About 0.1% by mass was adsorbed with respect to the total mass in terms of minutes. The charged voltage after the chargeability test of the support thus obtained was −3000V. The chargeability test was performed in the same manner as in Example 1.
そして、支持体の片面に上記膏体をホットメルト法により展膏して粘着剤層を形成した後、所望の大きさに裁断してテープ状の貼付剤を得た。
<比較例1>
表5に示す各成分をそれぞれ所定量秤量し、これらを実施例1と同様の条件で混合し、膏体を得た。
<Comparative Example 1>
A predetermined amount of each component shown in Table 5 was weighed and mixed under the same conditions as in Example 1 to obtain a paste.
一方、ポリエチレンテレフタレート織布(目付け100g/m2、縦モジュラス10N/5cm、横モジュラス5N/5cm)を支持体とした。この支持体の帯電性試験後の帯電圧は−6000Vであった。支持体の片面に上記膏体をホットメルト法により展膏して粘着剤層を形成した後、所望の大きさに裁断してテープ状の貼付剤を得た。 On the other hand, a polyethylene terephthalate woven fabric (weighing 100 g / m 2 , longitudinal modulus 10 N / 5 cm, lateral modulus 5 N / 5 cm) was used as a support. The charged voltage after the chargeability test of this support was -6000V. The plaster was spread on one side of the support by a hot melt method to form an adhesive layer, and then cut into a desired size to obtain a tape-like patch.
<比較例2>
表5に示す各成分をそれぞれ所定量秤量し、これらを実施例1と同様の条件で混合し、膏体を得た。
<Comparative example 2>
A predetermined amount of each component shown in Table 5 was weighed and mixed under the same conditions as in Example 1 to obtain a paste.
一方、ポリエチレンテレフタレート織布(目付け100g/m2、縦モジュラス10N/5cm、横モジュラス5N/5cm)を支持体とした。この支持体の帯電性試験後の帯電圧は−6000Vであった。支持体の片面に比較配合例2の膏体をホットメルト法により展膏して粘着剤層を形成した後、所望の大きさに裁断してテープ状の貼付剤を得た。 On the other hand, a polyethylene terephthalate woven fabric (weighing 100 g / m 2 , longitudinal modulus 10 N / 5 cm, transverse modulus 5 N / 5 cm) was used as a support. The charged voltage after the chargeability test of this support was -6000V. The plaster of Comparative Formulation Example 2 was spread on one side of the support by a hot melt method to form an adhesive layer, and then cut into a desired size to obtain a tape-like patch.
<比較例3>
ポリエチレンテレフタレート織布(目付け100g/m2、縦モジュラス10N/5cm、横モジュラス5N/5cm)に非イオン性界面活性剤(ナイスポ−ルEF−26:日華化学(株)製)を固形分換算で全質量に対し約0.1質量%吸着させた。このようにして得られた支持体の帯電性試験後の帯電圧は−3000Vであった。支持体の片面に比較例2の膏体をホットメルト法により展膏して粘着剤層を形成した後、所望の大きさに裁断してテープ状の貼付剤を得た。
<Comparative Example 3>
Polyethylene terephthalate woven fabric (100 g / m 2 per unit area, longitudinal modulus 10 N / 5 cm, transverse modulus 5 N / 5 cm) non-ionic surfactant (Nice Pol EF-26: manufactured by Nikka Chemical Co., Ltd.) as solid content And about 0.1% by mass with respect to the total mass. The charged voltage after the chargeability test of the support thus obtained was −3000V. After the plaster of Comparative Example 2 was spread on one side of the support by the hot melt method to form an adhesive layer, it was cut into a desired size to obtain a tape-like patch.
なお、比較例1〜3に用いた支持体の帯電性試験は実施例1と同様にして実施した。
<評価>
上記のようにして製造した実施例1〜4及び比較例1〜3の貼付剤につき、以下の点について評価した。
<Evaluation>
The following points were evaluated for the patches of Examples 1-4 and Comparative Examples 1-3 produced as described above.
(製造性)
上記実施例及び比較例の貼付剤の製造工程において、不良品の発生を観察した。支持体に蓄積した静電気により、製造中に支持体に皺、よれ等が生じたものを製造性が「不良」と、そのようなものが観察されず良好な製造性を有したものを製造性が「良好」と評価することとした。結果を表6に示す。
(Manufacturability)
In the manufacturing process of the patches of the above Examples and Comparative Examples, the occurrence of defective products was observed. Manufactured products with good manufacturability that are not observed when such defects are found to be "bad" due to static electricity accumulated on the substrate due to static or accumulated on the substrate during production. Was evaluated as “good”. The results are shown in Table 6.
(投錨性)
上記実施例及び比較例の貼付剤を健康成人男子10人の上腕内側に8時間貼付し、剥離した後の膏体残りを観察した。膏体残りが全くないものを「A」、一部膏体残りが認められたものを「B」、著しい膏体残りが認められたものを「C」とすることとした。結果を表6に示す。
(Throwing property)
The patches of the above Examples and Comparative Examples were applied to the inside of the upper arm of 10 healthy adult males for 8 hours, and the remaining plaster after detachment was observed. The case where there was no remaining plaster was designated as “A”, the case where some remaining plaster was recognized as “B”, and the case where significant remaining plaster was observed as “C”. The results are shown in Table 6.
(角質剥離性)
上記投錨性試験を行った貼付剤について、粘着剤層の表面を、0.25質量%のアミドブラックを含有するアミドブラック染色液で一昼夜にわたって染色した。染色液は、関東化学(株)製アミドブラック10Bを、水、酢酸及びメタノールの混合溶媒(水:酢酸:メタノール=45:10:45(質量比))に溶解することにより調整した。染色後、水洗および洗い液(水:酢酸:メタノール=8:2:90)で貼付剤を15分以上洗浄した。こうして処理した貼付剤について、粘着剤の表面を観察することにより角質剥離の有無を観察した。粘着剤層の表面において角質がほとんど認められなかった場合には、角質剥離を十分に防止できたとして「A」、粘着剤層の表面において角質がやや認められた場合には角質剥離がやや生じているものとして「B」、粘着剤表面において角質がかなり認められた場合には、著しい角質剥離があったものとして「C」と評価することとした。結果を表6に示す。
従って、本発明の貼付剤によれば、低コスト化が容易であり、粘着剤層と支持体との間に十分な粘着力を確保しながら、皮膚から剥離する際に角質剥離を十分に防止できることが確認された。
(Exfoliation)
About the patch which performed the said anchoring property test, the surface of the adhesive layer was dye | stained over the day and night with the amide black dyeing | staining liquid containing 0.25 mass% amide black. The staining solution was prepared by dissolving Amido Black 10B manufactured by Kanto Chemical Co., Ltd. in a mixed solvent of water, acetic acid and methanol (water: acetic acid: methanol = 45: 10: 45 (mass ratio)). After dyeing, the patch was washed with water and a washing solution (water: acetic acid: methanol = 8: 2: 90) for 15 minutes or more. About the patch processed in this way, the presence or absence of exfoliation was observed by observing the surface of the adhesive. When the stratum corneum is hardly recognized on the surface of the pressure-sensitive adhesive layer, it is assumed that the exfoliation can be sufficiently prevented, and “A” is obtained. In the case where the stratum corneum was considerably observed on the surface of the pressure-sensitive adhesive, it was evaluated as “C” because there was significant exfoliation. The results are shown in Table 6.
Therefore, according to the patch of the present invention, cost reduction is easy, and the keratin exfoliation is sufficiently prevented when exfoliating from the skin while ensuring sufficient adhesive force between the adhesive layer and the support. It was confirmed that it was possible.
Claims (8)
前記粘着剤層は、粘着性を有する基剤、オイル及び薬物を含有し、前記基剤は、少なくともエラストマーと粘着付与剤からなる粘着性組成物、及び/又は、総炭素数5以上の不飽和モノマーをモノマー単位として含む粘着性高分子、から構成され、
前記オイルは、前記粘着性組成物及び前記粘着性高分子と相溶性のあるオイルであり、
当該オイルの含有量は、前記粘着性組成物及び前記粘着性高分子の合計100質量部に対して60〜200質量部であり、
前記支持体は、帯電防止剤を含む不織布又は織布であることを特徴とする貼付剤。 In a patch comprising a support and an adhesive layer provided on the support,
The pressure-sensitive adhesive layer contains an adhesive base, oil, and drug, and the base is an adhesive composition composed of at least an elastomer and a tackifier, and / or unsaturated with a total carbon number of 5 or more. Composed of an adhesive polymer containing a monomer as a monomer unit,
The oil is an oil compatible with the adhesive composition and the adhesive polymer,
The content of the oil is 60 to 200 parts by mass with respect to a total of 100 parts by mass of the adhesive composition and the adhesive polymer,
The patch is characterized in that the support is a nonwoven fabric or a woven fabric containing an antistatic agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005197986A JP2007015963A (en) | 2005-07-06 | 2005-07-06 | Patch |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005197986A JP2007015963A (en) | 2005-07-06 | 2005-07-06 | Patch |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007015963A true JP2007015963A (en) | 2007-01-25 |
Family
ID=37753436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005197986A Pending JP2007015963A (en) | 2005-07-06 | 2005-07-06 | Patch |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2007015963A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008016077A1 (en) * | 2006-08-04 | 2008-02-07 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive preparation |
WO2009096315A1 (en) * | 2008-01-31 | 2009-08-06 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
WO2013187451A1 (en) * | 2012-06-12 | 2013-12-19 | 株式会社 ケイ・エム トランスダーム | Patch |
EP2851066A1 (en) * | 2013-09-23 | 2015-03-25 | LTS LOHMANN Therapie-Systeme AG | Fixation of vaccine formulations on devices for epidermal immunisation by oily adjuvants |
JPWO2018124089A1 (en) * | 2016-12-28 | 2019-10-31 | 久光製薬株式会社 | Patch |
WO2020175395A1 (en) * | 2019-02-27 | 2020-09-03 | 久光製薬株式会社 | Transdermal patch |
US11872320B2 (en) | 2021-02-25 | 2024-01-16 | Hisamitsu Pharmaceutical Co., Inc. | Method for treating osteoarthritis |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996008245A1 (en) * | 1994-09-16 | 1996-03-21 | Hisamitsu Pharmaceutical Co., Inc. | Patch for external use |
JPH0938212A (en) * | 1995-08-03 | 1997-02-10 | Okazaki Yoshiya | Molded cataplasm having biological electric charge removing function |
JPH0947469A (en) * | 1995-08-08 | 1997-02-18 | Sekisui Chem Co Ltd | Anti-static strap for emergency |
JPH09136829A (en) * | 1995-11-15 | 1997-05-27 | Sekisui Chem Co Ltd | Strap |
JP2000297032A (en) * | 1999-04-14 | 2000-10-24 | Hisamitsu Pharmaceut Co Inc | Patch |
JP2004043512A (en) * | 2003-11-10 | 2004-02-12 | Hisamitsu Pharmaceut Co Inc | Antiphlogistic and analgesic plaster |
WO2005011662A1 (en) * | 2003-07-31 | 2005-02-10 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
-
2005
- 2005-07-06 JP JP2005197986A patent/JP2007015963A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996008245A1 (en) * | 1994-09-16 | 1996-03-21 | Hisamitsu Pharmaceutical Co., Inc. | Patch for external use |
JPH0938212A (en) * | 1995-08-03 | 1997-02-10 | Okazaki Yoshiya | Molded cataplasm having biological electric charge removing function |
JPH0947469A (en) * | 1995-08-08 | 1997-02-18 | Sekisui Chem Co Ltd | Anti-static strap for emergency |
JPH09136829A (en) * | 1995-11-15 | 1997-05-27 | Sekisui Chem Co Ltd | Strap |
JP2000297032A (en) * | 1999-04-14 | 2000-10-24 | Hisamitsu Pharmaceut Co Inc | Patch |
WO2005011662A1 (en) * | 2003-07-31 | 2005-02-10 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
JP2004043512A (en) * | 2003-11-10 | 2004-02-12 | Hisamitsu Pharmaceut Co Inc | Antiphlogistic and analgesic plaster |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008016077A1 (en) * | 2006-08-04 | 2008-02-07 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive preparation |
US8455376B2 (en) | 2006-08-04 | 2013-06-04 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive preparation |
US9233184B2 (en) | 2006-08-04 | 2016-01-12 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive preparation |
US8809615B2 (en) | 2006-08-04 | 2014-08-19 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive preparation |
WO2009096315A1 (en) * | 2008-01-31 | 2009-08-06 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
US8382729B2 (en) | 2008-01-31 | 2013-02-26 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
AU2009210117B2 (en) * | 2008-01-31 | 2013-10-03 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
EP2246059A4 (en) * | 2008-01-31 | 2013-10-09 | Hisamitsu Pharmaceutical Co | ADHESIVE PLASTER |
TWI424857B (en) * | 2008-01-31 | 2014-02-01 | Hisamitsu Pharmaceutical Co | Adhesive agent |
JP5738531B2 (en) * | 2008-01-31 | 2015-06-24 | 久光製薬株式会社 | Patch |
WO2013187451A1 (en) * | 2012-06-12 | 2013-12-19 | 株式会社 ケイ・エム トランスダーム | Patch |
US10758494B2 (en) | 2012-06-12 | 2020-09-01 | KM Transderm Ltd. | Rivastigmine-containing adhesive patch |
JP2017137363A (en) * | 2012-06-12 | 2017-08-10 | 株式会社 ケイ・エム トランスダーム | Patches |
JPWO2013187451A1 (en) * | 2012-06-12 | 2016-02-08 | 株式会社 ケイ・エム トランスダーム | Patch |
WO2015040245A1 (en) * | 2013-09-23 | 2015-03-26 | Lts Lohmann Therapie-Systeme Ag | Fixation of vaccine formulations on devices for epidermal immunisation by oily adjuvants |
EP2851066A1 (en) * | 2013-09-23 | 2015-03-25 | LTS LOHMANN Therapie-Systeme AG | Fixation of vaccine formulations on devices for epidermal immunisation by oily adjuvants |
JPWO2018124089A1 (en) * | 2016-12-28 | 2019-10-31 | 久光製薬株式会社 | Patch |
US11020356B2 (en) | 2016-12-28 | 2021-06-01 | Hisamitsu Pharmaceutical Co., Inc. | Drug-containing patch |
US12178922B2 (en) | 2016-12-28 | 2024-12-31 | Hisamitsu Pharmaceutical Co., Inc. | Patch with DMSO in adhesive layer |
WO2020175395A1 (en) * | 2019-02-27 | 2020-09-03 | 久光製薬株式会社 | Transdermal patch |
US11872320B2 (en) | 2021-02-25 | 2024-01-16 | Hisamitsu Pharmaceutical Co., Inc. | Method for treating osteoarthritis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101392064B1 (en) | Patch and method for producing the same | |
CA2525470C (en) | External patch containing estrogen and/or progestogen | |
US20060193900A1 (en) | Pressure sensitive adhesive and patch | |
WO2002069942A1 (en) | Adhesive patch | |
KR20090009235A (en) | Transdermal absorption preparation containing tamsulosin | |
EP2599501A1 (en) | Adhesive patch for medical use | |
WO2004019988A1 (en) | Adhesive patch | |
WO2006095820A1 (en) | Adhesive and adhesive patch | |
JP4199485B2 (en) | Patch | |
JP6014813B2 (en) | Transdermal absorption preparation and adhesive sheet for skin application | |
WO2014159582A1 (en) | Amphetamine transdermal compositions with acrylic block copolymer | |
US6436433B1 (en) | Transdermal or topical plaster system with a polyacrylate matrix with improved physical properties | |
JP2007015963A (en) | Patch | |
US10292941B2 (en) | Adhesive patch | |
JP6528154B2 (en) | Patch preparation containing bisoprolol | |
JP2688778B2 (en) | Patch for disease treatment | |
JPWO2006093066A1 (en) | Adhesive substrate and medical patch preparation containing the adhesive substrate | |
CN105517544A (en) | Bisoprolol-containing adhesive patch | |
KR20190053853A (en) | Patch | |
JPH0565224A (en) | Gelatinous material and therapeutic gel pharmaceutical using the same | |
JP4664281B2 (en) | Patch | |
JP2007031322A (en) | Plaster | |
JP5020554B2 (en) | Non-aqueous adhesive composition and patch using the same | |
JP5089376B2 (en) | Adhesives and patches | |
JPH07157423A (en) | Percutaneously absorbable cataplasm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080515 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110616 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110621 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111213 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120208 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120306 |